pipeline – anthera pharmaceuticals phone infoantheracom pipeline siteadministrator t pipeline pipelinesollpura blisibimod publications sollpura – anthera pharmaceuticals phone infoantheracom sollpura siteadministrator t sollpura sollpura represents the potentially first soluble stable and nonpig derived pancreatic enzyme replacement therapy pert to offer a novel solution to patients especially young children and adults who are either unable to swallow multiple pills or are forced to use gastric tubes in order to maintain appropriate nutritional health unlike other enzyme products for the treatment of exocrine pancreatic insufficiency epi sollpura’s chemical characteristics its solubility and stability make it an ideal product in either a capsule or sachet formulation which can be conveniently coadministered with a variety of food products sollpura provides numerous advantages over current approved perts studies anthera is conducting two studies with sollpura result study the purpose of the result study is to evaluate the noninferiority of sollpura compared to approved porcinederived entericallycoated pancreatic enzyme replacement therapy when administered to patients with cystic fibrosis and endocrine pancreatic insufficiency learn more simplicity study the simplicity study will evaluate the safety and efficacy of sollpura powder for oral solution supplied in sachets learn more pipelinesollpura blisibimod publications anthera pharmaceuticals inc nasdaqanth anthera pharmaceuticals inc anth product news news  stocknewscom     follow us stocktwits twitter anthera pharmaceuticals inc anth product news news anth – commences screening in europe in the result phase  clinical study of sollpura for exocrine pancreatic insufficiency due to cystic fibrosis expects topline data by end of  or early  jul    am  by stocknewscom staff product news key facts surrounding this news item anth had a powr rating of d sell coming into today anth was  below its day moving average coming into today anth was  below its day moving average coming into today anth was  below its day moving average coming into today anth was  below its day moving average coming into today anth was  below its day moving average coming into today anth had returned  yeartodate leading up to today’s news versus a  return from the benchmark sp  during the same period more info about anthera pharmaceuticals inc anth anthera pharmaceuticals is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs the company was founded in  and is based in hayward california view our full anth ticker page with ratings news and more anth at a glance anth current powr rating™ overall powr rating™ anth current price   more anth ratings data and news anth price reaction the day of this event jul  anth closing price anth volume from avgleading up to this eventanth mo returnafter this eventanth day returnanth day returnanth day return anth price chart more anthera pharmaceuticals inc anth news view all eventdate symbol news detail start price end price change powr rating loading please wait view all anth news page generated in  seconds press releases  anthera phone infoantheracom about us about us management board of directors scientific advisory board pipeline pipeline sollpura blisibimod publications clinical studies clinical studies solution simplicity bright · sc for investors corporate profile events  presentations press releases analyst coverage stock information corporate governance financials  filings investor contact contact us about us about us management board of directors scientific advisory board pipeline pipeline sollpura blisibimod publications clinical studies clinical studies solution simplicity chablissc for investors corporate profile events  presentations press releases analyst coverage stock information corporate governance financials  filings investor contact contact us go to about us about us management board of directors scientific advisory board pipeline pipeline sollpura blisibimod publications clinical studies clinical studies solution simplicity chablissc for investors corporate profile events  presentations press releases analyst coverage stock information corporate governance financials  filings investor contact contact us go to about us about us management board of directors scientific advisory board pipeline pipeline sollpura blisibimod publications clinical studies clinical studies solution simplicity chablissc for investors corporate profile events  presentations press releases analyst coverage stock information corporate governance financials  filings investor contact contact us press releases year all years              sort by date descending date ascending update   press releases   date title and summary view jul   anthera pharmaceuticals announces result phase  clinical study of sollpura will be included in the cystic fibrosis foundation therapeutics development network hayward calif july   globe newswire  anthera pharmaceuticals nasdaqanth today announced that the result phase  clinical study of sollpura for exocrine pancreatic insufficiency due to cystic fibrosis has been approved by the cystic fibrosis foundation therapeutics development network cff tdn protocol review committee the cff t pdf add to briefcase file is in briefcase jul   anthera announces expansion of screening in european sites in phase  result clinical study of sollpura study is being conducted in the us europe and israeltop line data expected end of  or early  hayward calif july   globe newswire  anthera nasdaqanth today announced that it has commenced screening in europe in the result phase  clinical study of sollpura for exocrine pancreatic insufficiency epi due to cystic fibros pdf add to briefcase file is in briefcase may   anthera announces first patient screened in result pivotal phase  clinical study of sollpura fourweek noninferiority coefficient of fat absorption cfa primary endpoint comparing sollpura to pancreaze in patients with exocrine pancreatic insufficiency due to cystic fibrosisstudy design leverages input from the us fda and cf communitytarget enrollment of  patients  years of age and oldertop line data expected end of  or early  pdf add to briefcase file is in briefcase may   anthera pharmaceuticals provides business update and reports  first quarter financial results result pivotal phase  study of sollpura is expected to screen the first patient in mayfavorable trends on weight height and body mass index bmi from the extension period of the solution study of sollpuracompletion of dosing in the phase  brightsc study of blisbimod in patients with iga nephropathyclosing of initial  million public off pdf add to briefcase file is in briefcase apr   anthera pharmaceuticals announces for reverse split of stock hayward calif april   globe newswire  anthera pharmaceuticals inc nasdaqanth announced today that it has filed a certificate of amendment to its amended and restated certificate of incorporation to effect a for reverse stock split of its common stock effective as of april   at  pm eastern time  a certificate  pdf add to briefcase file is in briefcase apr   anthera announces completion of dosing in the phase  brightsc study of blisibimod in patients with iga nephropathy hayward calif april   globe newswire  anthera pharmaceuticals nasdaqanth today announced the completion of dosing in the randomized doubleblind placebo controlled phase  brightsc study of blisibimod in patients with iga nephropathy igan  after week  patients were given the opportunity to continue blinded treatment fo pdf add to briefcase file is in briefcase mar   anthera announces positive results from the extension period of the solution study of sollpura sollpura demonstrated comparable maintenance in key measurements of height weight and bmisollpura was well tolerated throughout the week extension period hayward calif march   globe newswire  anthera pharmaceuticals inc nasdaqanth today announced the findings from the extension period of the phase  solution noninferior pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals announces pricing of  million public offering of common stock and warrants hayward calif march   globe newswire  anthera pharmaceuticals inc nasdaqanth the company today announced the pricing of an underwritten public offering of  shares of its common stock at a price of  per share and two tranches of warrants to purchase an aggregate of  shares of its common stock the gr pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals announces proposed public offering of common stock and warrants hayward calif march   globe newswire  anthera pharmaceuticals inc nasdaqanth the company today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering  in addition the company intends to grant the underwriters a day op pdf add to briefcase file is in briefcase feb   anthera pharmaceuticals provides business update and reports  fourth quarter and fiscal year financial results solution study with sollpura™ missed noninferiority endpoint by  prompting new phase  studydata monitoring committee issued recommendation to continue simplicity study with sollpura™blisibimod for the treatment of iga nephropathy demonstrated positive trends at week blisibimod for the treatment of systemic lupus terminatedcraig t pdf add to briefcase file is in briefcase dec   anthera announces the phase  solution study with sollpura™ in cystic fibrosis patients with exocrine pancreatic insufficiency demonstrates encouraging results  additional study needed sollpura narrowly missed the primary endpoint for change in the coefficient of fat absorption cfa noninferiority marginsollpura demonstrated noninferiority in the per protocol cfa analysissollpura demonstrated noninferiority in coefficient of nitrogen absorption cna analysesanthera will initiate a new study to demonstrate the efficacy of sol pdf add to briefcase file is in briefcase dec   anthera pharmaceuticals announces continuation of simplicity study of sollpura™ following positive dmc review hayward calif dec   globe newswire  anthera pharmaceuticals inc nasdaqanth today announced that the data monitoring committee dmc completed its preplanned safety review of the simplicity clinical study of sollpura supplied as a powder for oral solution in an initial cohort of cystic fibrosis patients  seven years of age and pdf add to briefcase file is in briefcase dec   anthera announces leadership transition in preparation of commercialization of sollpura and future development of blisibimod for iga nephropathy j craig thompson promoted to chief executive officer and appointed to the board of directorspaul f truex appointed as executive chairman of the boarddr christopher henney stepped down as chairman of the board but will remain as director hayward calif dec   globe newswire  today the anthera pharmaceuticals inc nasdaqanth boa pdf add to briefcase file is in briefcase dec   anthera reports blisibimod brightsc iga nephropathy continues to demonstrate positive trends in the week  analysis lower proteinuria in blisibimod versus placebo treated patientschanges in circulating bcells and serum immunoglobulins consistent with baff inhibition hayward calif dec   globe newswire  anthera pharmaceuticals inc nasdaqanth today announced positive trends from the week  analysis of the phase  brightsc proofofconcept pdf add to briefcase file is in briefcase nov   anthera pharmaceuticals announces participation at upcoming healthcare conferences pdf add to briefcase file is in briefcase nov   anthera announces that the blisibimod chablissc phase  study did not achieve the primary endpoint in patients with active systemic lupus erythematosus assessing next steps for blisibimod for the treatment of systemic lupus erythematosuscontinuing to explore blisibimod as treatment for iga nephropathy  phase  data in decembersollpuratm solution phase  study in exocrine pancreatic insufficiency on track for topline data in december hayward calif nov   globe newswire  anthera  pdf add to briefcase file is in briefcase nov   anthera pharmaceuticals provides business update and reports  third quarter financial results blisibimod topline data from the phase  chablissc study in severe lupus patients is imminentdata and safety monitoring board recommendation to continue solution study with sollpura™fda type c meeting in september validated basis for bla filing and manufacturing approach for sollpura™closing of initial  million registered direct of pdf add to briefcase file is in briefcase nov   anthera announces that data from the phase  brightsc study has been accepted as a late breaking abstract at the asn kidney week  annual meeting hayward calif nov   globe newswire  anthera pharmaceuticals inc nasdaqanth today announced that an abstract of the interim data from the phase  brightsc clinical study evaluating the treatment effect of blisibimod in patients with biopsyproven iga nephropathy igan has been accepted as a latebreaking poster presentation a pdf add to briefcase file is in briefcase nov   anthera pharmaceuticals to provide business update and report  third quarter financial results on november  pdf add to briefcase file is in briefcase sep   anthera pharmaceuticals announces initial  million closing of a potential  million registered direct offering to biotechnology value fund and rock springs capital hayward calif sept   globe newswire  anthera pharmaceuticals inc nasdaqanth today announced that it has agreed to sell preferred convertible stock in two tranches to biotechnology value fund lp and other affiliates of bvf partners lp bvf and rock springs capital for initial proceeds of  million with an option fo pdf add to briefcase file is in briefcase aug   anthera pharmaceuticals announces appointment of dr william shanahan jr as chief medical officer hayward calif aug   globe newswire  anthera pharmaceuticals inc nasdaqanth today announced the appointment of william shanahan md jd as chief medical officer  in his role as chief medical officer dr shanahan will bring his experience as a rheumatologist and in drug development to lead the blisibimod lupus program and  pdf add to briefcase file is in briefcase aug   anthera pharmaceuticals announces positive dsmb review in phase  solution study of sollpura™ hayward calif aug   globe newswire  anthera pharmaceuticals inc nasdaqanth today announced that the data and safety monitoring board dsmb completed its first preplanned safety review of the phase  solution clinical study of sollpura™ in cystic fibrosis patients with exocrine pancreatic insufficiency the dsmb had no pdf add to briefcase file is in briefcase aug   anthera pharmaceuticals provides business update and reports  second quarter financial results met enrollment target in solution study and enrolled first patient in simplicity study of sollpura™successful sachet manufacturing to support simplicity study and commercialscale lipase demonstration batchfirst patient enrolled in pivotal chablis  clinical study of blisibimodpositive trends from analysis of brightsc phase  clinical stud pdf add to briefcase file is in briefcase aug   anthera pharmaceuticals announces completion of dosing in chablissc phase  clinical study with blisibimod hayward calif aug   globe newswire  anthera pharmaceuticals inc nasdaqanth today announced that the last patient in the phase  chablissc clinical study evaluating blisibimod for the treatment of systemic lupus erythematosus received their final study dose on july th  as described in the protocol patients are followed  pdf add to briefcase file is in briefcase jun   anthera provides clinical program updates for blisibimod and sollpura® positive trends from brightsc proofofconcept study  study to continuesolution study with sollpura completed patient screening ahead of schedule  data in first patients screened in phase  chablis  study of blisibimod in seropositive lupus patientschablissc results to be reported in the third quarter  recent dsmb review found no safet pdf add to briefcase file is in briefcase jun   anthera pharmaceuticals announces presentation at jmp securities life sciences conference pdf add to briefcase file is in briefcase may   anthera pharmaceuticals announces presentation at jefferies healthcare conference pdf add to briefcase file is in briefcase may   anthera pharmaceuticals provides business update and reports  first quarter financial results solution clinical study of sollpura™ expanded to europe israel and canada in addition to ongoing us enrollmentcraig thompson named as president and chief operating officerappointment of dr james pennington to interim chief medical officerenrollment of brightsc phase  clinical study in iga nephropathy completedbulk manufacturing campaign f pdf add to briefcase file is in briefcase apr   anthera pharmaceuticals appoints brent furse to board of directors hayward calif april   globe newswire  anthera pharmaceuticals inc nasdaqanth today announced the appointment of brent furse to its board of directors mr furse has over  years of healthcare commercial leadership experience with extensive experience in the areas of sales and marketing commercial product launch and partn pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals provides business update and reports  fourth quarter and fiscal year financial results solution clinical study of oral sollpura™ enrollment to begin soon in europedata from brightsc study in iga nephropathy planned for q addition of craig thompson as president and chief operating officerappointment of dr james pennington to interim chief medical officer hayward calif march   globe newswire  anthera phar pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals announces appointment of dr james pennington as interim chief medical officer hayward calif march   globe newswire  anthera pharmaceuticals inc nasdaqanth today announced the appointment of james pennington md as interim chief medical officer following the companys acceptance of colin hislops resignation effective april st  our development programs have progressed extensively during col pdf add to briefcase file is in briefcase jan   anthera pharmaceuticals announces appointment of craig thompson as president and chief operating officer and dr chuck olson as chief technology officer hayward calif jan   globe newswire  anthera pharmaceuticals inc  nasdaqanth today announced the appointment of craig thompson as president and chief operating officer  in this role mr thompson will oversee both of antheras late stage development programs and commercial preparation efforts  anthera also announced the appoin pdf add to briefcase file is in briefcase nov   anthera pharmaceuticals provides business update and reports third quarter  financial results closed  million public offering in july including full exercise of underwriters option to purchase additional sharescompleted capsule manufacturing in support of the solution clinical studyinitiated the solution clinical study of oral sollpura™ to regain all japan rights to blisibimod following termination of asia partnership hayward ca pdf add to briefcase file is in briefcase oct   anthera pharmaceuticals announces presentation at healthcare conferences acr reception and timing of third quarter financial results hayward calif oct   globe newswire  anthera pharmaceuticals inc nasdaqanth today announced the companys attendance at the following healthcare conferences november th  mr paul f truex president and chief executive officer will host oneonone meetings at the  citi global healthcare conference at the palac pdf add to briefcase file is in briefcase oct   anthera announces initiation of the solution clinical study of oral sollpurar liprotamase unitmatched therapy of nonporcine origin in people with cystic fibrosis study to enroll approximately  patients with exocrine pancreatic insufficiency more than  clinical sites around the united states and europe are expected to participate anthera to host reception at the north american cystic fibrosis conference to discuss the solution program hayward calif oct   globe pdf add to briefcase file is in briefcase sep   anthera announces termination of blisibimod partnership in japan by zenyaku anthera will regain all worldwide rights for blisibimod without cost no patients were enrolled in the brightsc study or any other clinical study in japan zenyaku is required to continue various funding obligations during the termination period no effect on blisibimod lupus program or sollpura development program  pdf add to briefcase file is in briefcase aug   anthera pharmaceuticals reports  second quarter and operational update reached enrollment target of  subjects in phase  chablissc clinical study with blisibimod additional data on patientreported outcomes from phase b pearlsc blisibimod clinical study presented at eular increased cash position by an incremental  million through public offering in july addition to the russell  pdf add to briefcase file is in briefcase jul   anthera pharmaceuticals to report  second quarter and operational update on august  hayward calif july   globe newswire  anthera pharmaceuticals inc nasdaqanth today announced that it plans to issue a press release reporting its  second quarter and operational update after the close of the market on monday august   about anthera pharmaceuticals anthera pharmaceuticals is a biopharmac pdf add to briefcase file is in briefcase jul   anthera pharmaceuticals announces completion of public offering of common stock and exercise in full of underwriters option to purchase additional shares hayward calif july   globe newswire  anthera pharmaceuticals inc nasdaqanth today announced that it has completed the previously announced underwritten public offering of  shares of its common stock offered at a price of  per share which includes the exercise in full by the underwriters of their option to purchas pdf add to briefcase file is in briefcase jul   anthera pharmaceuticals announces pricing of public offering of common stock hayward calif july   globe newswire  anthera pharmaceuticals inc nasdaqanth today announced the pricing of an underwritten public offering of  shares of its common stock offered at a price of  per share the company estimates that the gross proceeds from the offering before deducting underwriting discounts and comm pdf add to briefcase file is in briefcase jul   anthera pharmaceuticals announces proposed public offering of common stock hayward calif july   globe newswire  anthera pharmaceuticals inc nasdaqanth today announced that it intends to offer and sell shares of its common stock in an underwritten public offering the company expects to grant the underwriters a day option to purchase up to an additional  of the shares of common stock offered in the  pdf add to briefcase file is in briefcase jun   anthera pharmaceuticals added to the russell r and russell r indexes hayward calif june   globe newswire  anthera pharmaceuticals inc nasdaqanth a biopharmaceutical company focused on developing and commercializing products to treat serious and lifethreatening diseases today announced that as of the close of the market on friday june th  the company was added to the russell ®  pdf add to briefcase file is in briefcase jun   anthera pharmaceuticals has reached enrollment target in chablissc phase  clinical trial with blisibimod hayward calif june   globe newswire  anthera pharmaceuticals inc nasdaqanth today announced that it has met the enrollment target of its chablissc phase  clinical trial evaluating blisibimod for the treatment of lupus final data from the trial is expected in the second half of  reaching our enrollment target for pdf add to briefcase file is in briefcase jun   anthera pharmaceuticals announces additional data on patientreported outcomes from phase b pearlsc blisibimod study hayward calif june   globe newswire  anthera pharmaceuticals inc nasdaqanth a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs today announced that additional data from its phase b pearlsc study will be presented in a pos pdf add to briefcase file is in briefcase may   anthera pharmaceuticals to present at annual jefferies healthcare conference hayward calif may   globe newswire  anthera pharmaceuticals inc nasdaqanth a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs announced today that paul f truex president and chief executive officer will present a corpor pdf add to briefcase file is in briefcase may   anthera pharmaceuticals reports  first quarter and operational update completed interim analysis from phase  trial with blisibimod for systematic lupus erythematosus completed interim analysis from phase  trial with blisibimod for iga nephropathy increased cash position by  million through equity investment by zenyaku and equity offering received  million research award from cys pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals announces completion of public offering of common stock hayward calif march   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced that it has completed the previously announced underwritten public offering of  shares of its common stock offered at a price of  per share  in addition anthera has granted the underwriters a day option to purchase up to pdf add to briefcase file is in briefcase mar   anthera announces  million research award from cystic fibrosis foundation therapeutics for development of sollpura  a novel enzyme therapy hayward calif march   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced it has received an award from cystic fibrosis foundation therapeutics inc of up to  million to support the manufacturing and clinical development of antheras novel pancreatic enzyme replacement therapy sollpura™ liprotamase   c pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals announces pricing of public offering of common stock hayward calif march   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced the pricing of an underwritten public offering of  shares of its common stock offered at a price of  per share the company estimates that the gross proceeds from the offering before deducting underwriting discounts and commi pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals announces proposed public offering of common stock hayward calif march   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced that it intends to offer and sell shares of its common stock in an underwritten public offering the company expects to grant the underwriters a day option to purchase up to an additional  of the shares of common stock offered in the p pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals announces completion of interim analysis from phase  trial with blisibimod for iga nephropathy hayward calif march   prnewswire  anthera pharmaceuticals inc nasdaq anth in collaboration with its partner zenyaku kogyo co ltd today announced that the brightsc study of blisibimod in patients with iga nephropathy igan should continue to completion as planned this follows the successful completion of an interim futility pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals reports  fourth quarter and fiscal year financial results operational update and recent event highlights hayward calif march   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced financial results and an operational update for the fourth quarter and year ended december   net loss for the fourth quarter and year ended december   was  million and  million respectively compared to   pdf add to briefcase file is in briefcase feb   anthera pharmaceuticals to present at cowen  co healthcare conference hayward calif feb   prnewswire  anthera pharmaceuticals inc nasdaqanth announced today that paul f truex president and chief executive officer will present a corporate update on the progress of the companys development programs at the th annual cowen  company health care conference anthera will present from  pdf add to briefcase file is in briefcase feb   anthera pharmaceuticals regains compliance with nasdaq listing requirements hayward calif feb   prnewswire  anthera pharmaceuticals nasdaq anth today announced that the company has received formal notification from the nasdaq stock market nasdaq indicating that the company has regained compliance with listing rule ba which requires a minimum of  in stockholders equity or maint pdf add to briefcase file is in briefcase feb   anthera pharmaceuticals announces completion of interim analysis from phase  trial with blisibimod for systemic lupus erythematosus hayward calif feb   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced the successful completion of an interim analysis of its phase  trial chablissc of blisibimod in patients with systemic lupus erythematosus and that the study should continue to completion as planned an independent statistician conducted pdf add to briefcase file is in briefcase jan   anthera pharmaceuticals announces appointment of klara a dickinson as senior vice president chief regulatory officer hayward calif jan   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced the appointment of klara a dickinson as senior vice president chief regulatory officer were fortunate to have klara join our team as we enter this phase of our product development efforts said paul f truex antheras president pdf add to briefcase file is in briefcase dec   anthera pharmaceuticals announces lupus symposium during  jp morgan healthcare conference hayward calif dec   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced that it is inviting its shareholders and investors to a symposium on systemic lupus erythematosus sle at  pm on wednesday january th at the mystic hotel in san francisco ca right patient right therapya symposium on syste pdf add to briefcase file is in briefcase dec   anthera pharmaceuticals licenses japan rights for blisibimod to zenyaku kogyo co ltd hayward calif dec   prnewswire  anthera pharmaceuticals inc nasdaq anth announced today that anthera and zenyaku kogyo co ltd of tokyo japan executed an exclusive license agreement for the development and commercialization of subcutaneous blisibimod in japan and potentially other countries throughout asia  anthera retains f pdf add to briefcase file is in briefcase nov   anthera pharmaceuticals to present at annual piper jaffray healthcare conference hayward calif nov   prnewswire  anthera pharmaceuticals inc nasdaq anth announced today that paul f truex president and chief executive officer will present a corporate update at the  annual piper jaffray healthcare conference anthera will present at pm et december rd at the palace hotel in new york city pdf add to briefcase file is in briefcase nov   anthera and patheon sign manufacturing agreement for liprotamase phase iii registration trial hayward calif nov   prnewswire  anthera pharmaceuticals inc nasdaq anth announced today it has signed a manufacturing and supply agreement with the patheon® division of dpx holdings bv  the contract provides for patheon to support the production of the sollpura® clinical drug product for antheras phase iii registrat pdf add to briefcase file is in briefcase nov   anthera pharmaceuticals reports  third quarter financial results and operational update hayward calif nov   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced financial results and operational update for the third quarter ended september   net loss for the three months ended september   was  million compared to  million for the same period in  the increase in n pdf add to briefcase file is in briefcase oct   anthera pharmaceuticals announces update on strategic partnership discussions for blisibimod hayward calif oct   prnewswire  anthera pharmaceuticals inc nasdaq anth today confirmed it is engaged in potential partnership negotiations for blisibimod for both lupus and iga nephropathy in territories outside the united states anthera does not intend to communicate further regarding these discussions unless and until  pdf add to briefcase file is in briefcase jul   anthera pharmaceuticals reports  second quarter financial results and operational update hayward calif july   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced financial results and operational update for the second quarter ended june   net loss for the three months ended june   was  million compared to  million for the same period in  the decrease in net loss i pdf add to briefcase file is in briefcase jul   anthera pharmaceuticals announces acquisition of sollpura® liprotamase for exocrine pancreatic insufficiency from eli lilly and company hayward calif july   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced that it has acquired sollpura liprotamase a novel investigational pancreatic enzyme replacement therapy pert from eli lilly and company  sollpura is a soluble stable and nonporcine enzyme product intended for the treatment of patien pdf add to briefcase file is in briefcase jun   anthera pharmaceuticals appoints brian r mueller to board of directors hayward calif june   prnewswire  anthera pharmaceuticals inc nasdaqanth a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases today announced the appointment of brian r mueller to its board of directors and as chairman of the audit committee of the board of directors  mr  pdf add to briefcase file is in briefcase jun   anthera pharmaceuticals appoints dr philip sager to board of directors hayward calif june   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases today announced the appointment of dr philip sager md facc faha fhrs to its board of directors dr sager is a fellow of the american  pdf add to briefcase file is in briefcase may   anthera pharmaceuticals reports  first quarter financial results and operational update hayward calif may   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced financial results and operational update for the first quarter ended march   first quarter  financial results net loss for the first quarter ended march   was  million compared to  million for the  pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals announces personnel changes hayward calif march   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases today announced the appointment of steven engle to and the departure of dr james healy md phd from its board of directors steves exten pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals reports  fourth quarter and fiscal year financial results and operational update hayward calif march   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced financial results and operational update for the fourth quarter and year ended december   fourth quarter and fiscal year  financial results net loss for the fourth quarter and year ended december   was  pdf add to briefcase file is in briefcase jan   anthera pharmaceuticals to present at leerink swann cowen  co and bio ceo healthcare conferences hayward calif jan   prnewswire  anthera pharmaceuticals inc nasdaqanth a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases announced today that paul f truex president and chief executive officer will present a corporate update on the progress of the companys developme pdf add to briefcase file is in briefcase nov   anthera pharmaceuticals to present at annual piper jaffray healthcare conference hayward calif nov   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases announced today that paul f truex president and chief executive officer and may liu senior vice president of finance and administration will pr pdf add to briefcase file is in briefcase oct   anthera pharmaceuticals reports  third quarter financial results clinical and regulatory update hayward calif oct   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced financial results clinical and regulatory update for the quarter ended september   third quarter  financial results net loss for the third quarter of  decreased to  million from  million and loss p pdf add to briefcase file is in briefcase sep   anthera pharmaceuticals announces emerging data from phase  openlabel extension study to be presented at the acrarhp  annual scientific meeting hayward calif sept   prnewswire  anthera pharmaceuticals nasdaq anth a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases announced today that emerging data from its phase b pearlsc study and subsequent openlabel extension study will be presented by dr richard furie at t pdf add to briefcase file is in briefcase jul   anthera pharmaceuticals reports  second quarter financial results hayward calif july   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced financial results and business highlights for the quarter ended june   second quarter  financial results loss from operations decreased in the second quarter of  to  million from  million in the seco pdf add to briefcase file is in briefcase jul   anthera pharmaceuticals announces for reverse split of stock haywood calif july   prnewswire  anthera pharmaceuticals inc nasdaq anth announced today that it has filed a certificate of amendment to its amended and restated certificate of incorporation to effect a for reverse stock split of its common stock effective as of pm eastern time today  a certificate of amendment to effec pdf add to briefcase file is in briefcase jun   anthera announces initiation of brightsc phase  clinical study in iga nephropathy with blisibimod hayward calif june   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with autoimmune disorders today announced it has initiated the brightsc phase  study of blisibimod a novel inhibitor of bcell activating factor baff for the treatment o pdf add to briefcase file is in briefcase jun   anthera pharmaceuticals announces receipt of nasdaq notice hayward calif june   prnewswire  anthera pharmaceuticals inc nasdaq anth the company a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases today announced that it received a staff determination letter the notice on ju pdf add to briefcase file is in briefcase jun   anthera pharmaceuticals announces personnel changes hayward calif june   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced the appointment of may liu as its senior vice president finance and administration  in this position ms liu will oversee the finance investor relations and general administration functions of anthera in addition to her role as principal  pdf add to briefcase file is in briefcase may   anthera pharmaceuticals to present at annual jefferies healthcare conference hayward calif may   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases announced today that paul f truex president and chief executive officer and dr colin hislop senior vice president and chief medical officer wil pdf add to briefcase file is in briefcase may   anthera pharmaceuticals reports  first quarter financial results hayward calif may   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced financial results and business highlights for the quarter ended march st  first quarter  financial results loss from operations which included a nonrecurring and noncash charge of approximately  million in  pdf add to briefcase file is in briefcase may   anthera pharmaceuticals announces additional data from phase b pearlsc blisibimod study hayward calif may   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases today announced that additional data from its phase b pearlsc study will be presented in two lecture sessions at the european league against rheumat pdf add to briefcase file is in briefcase may   anthera announces first quarter  financial report and conference call hayward calif may   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases will release its first quarter  financial report after market close on monday may th anthera will host a corporate update conference call on m pdf add to briefcase file is in briefcase apr   anthera refinances existing debt with new  million credit facility and secures  million committed equity financing facility hayward calif april   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced that it has secured a new  million debt financing facility through a syndicate led by midcap financial sbic lp midcap financial a pdf add to briefcase file is in briefcase mar   anthera initiates chablissc phase  clinical study in lupus with blisibimod hayward calif march   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today announced it has initiated the chablissc phase  study of blisibimod a novel inhibitor of bcell activating factor baff pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals reports  fourth quarter and fiscal year financial results hayward calif march   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced financial results and business highlights for the quarter and fiscal year ended december   fourth quarter and fiscal year  financial results total operating expenses for the fourth quarter ended december   pdf add to briefcase file is in briefcase mar   anthera announces data from the phase b pearlsc study will be presented at the th international congress on systemic lupus erythematosus hayward calif march   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today announced its abstract entitled blisibimod an emerging subcutaneous biologic therapy for patients with active moderateto pdf add to briefcase file is in briefcase feb   anthera pharmaceuticals to present at the  leerink global healthcare conference hayward calif feb   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today announced paul f truex antheras president and chief executive officer will present at the  leerink global healthcare co pdf add to briefcase file is in briefcase feb   anthera pharmaceuticals announces departure of georgina kilfoil hayward calif feb   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced that senior vice president of product development georgina kilfoil has notified the company she will leave the company effective february   to pursue other opportunities the board and management of anthera would like to thank  pdf add to briefcase file is in briefcase jan   anthera pharmaceuticals announces completion of public offering of common stock hayward calif jan   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced that it has completed the previously announced underwritten public offering of  shares of its common stock offered at a price of  per share  in addition anthera has granted the underwriters a day option to purchase up to  pdf add to briefcase file is in briefcase jan   anthera pharmaceuticals announces pricing of public offering of common stock hayward calif jan   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced the pricing of an underwritten public offering of  shares of its common stock offered at a price of  per share  the company estimates that the gross proceeds from the offering before deducting underwriting discounts and comm pdf add to briefcase file is in briefcase jan   anthera pharmaceuticals announces proposed public offering of common stock hayward calif jan   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced that it intends to offer and sell shares of its common stock in an underwritten public offering  the company expects to grant the underwriters a day option to purchase up to an additional  of the shares of common stock offered in the p pdf add to briefcase file is in briefcase nov   anthera announces data from the phase b pearlsc study presented at the  asian lupus summit hayward calif nov   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today announced additional data from its phase b pearlsc study was presented in a poster at the  asian lupus summit the post pdf add to briefcase file is in briefcase nov   anthera pharmaceuticals to present at the piper jaffray health care conference hayward calif nov   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today announced that paul f truex antheras president and chief executive officer will present at the piper jaffray health care  pdf add to briefcase file is in briefcase nov   anthera announces additional data from the phase b pearlsc presented at the acrarhp  annual scientific meeting hayward calif nov   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today announced additional data from its phase b pearlsc study presented in a late breaking poster at the  annual scientific  pdf add to briefcase file is in briefcase nov   anthera announces the phase b pearlsc data has been accepted as a late breaking poster presentation at the acrarhp  annual scientific meeting hayward calif nov   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today announced that an abstract of the results from the phase b pearlsc clinical study examining the treatment effect of blisibim pdf add to briefcase file is in briefcase oct   anthera pharmaceuticals reports  third quarter financial results and provides clinical progress update hayward calif oct   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced financial results and business highlights for the quarter ended september   financial results and corporate update total operating expenses for the third quarter ended september   were  million as compar pdf add to briefcase file is in briefcase oct   anthera announces third quarter  financial report and conference call hayward calif oct   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders will release its third quarter  financial report after market close on wednesday october   anthera will host a confere pdf add to briefcase file is in briefcase sep   anthera announces the advancement of blisibimod into phase  development for patients with systemic lupus erythematosus sle hayward calif sept   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today provided an update on regulatory discussions for the global development of blisibimod  end of phase  discussions with the  pdf add to briefcase file is in briefcase aug   anthera pharmaceuticals reports  second quarter financial results and provides clinical progress update hayward calif aug   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced financial results and business highlights for the quarter ended june   financial results total operating expenses for the second quarter ended june   were  million as compared to  million for the fir pdf add to briefcase file is in briefcase aug   anthera to report second quarter  financial results hayward calif aug   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today announced it will report its unaudited financial results for the second quarter ended june   on tuesday august   pdf add to briefcase file is in briefcase jul   anthera pharmaceuticals announces exercise in full of overallotment option and completion of public offering of common stock hayward calif july   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced that it has completed the previously announced underwritten public offering of  shares of its common stock offered at a price to the public of  per share  in addition the company has sold  shares of its common stoc pdf add to briefcase file is in briefcase jul   anthera pharmaceuticals announces pricing of public offering of common stock hayward calif july   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced the pricing of an underwritten public offering of  million shares of its common stock offered at a price of  per share  the company estimates that the gross proceeds from the offering before deducting underwriting discounts and comm pdf add to briefcase file is in briefcase jul   anthera pharmaceuticals announces proposed public offering of common stock hayward calif july   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced that it intends to offer and sell shares of its common stock in an underwritten public offering  the company expects to grant the underwriters a day option to purchase up to an additional  of the shares of common stock offered in the  pdf add to briefcase file is in briefcase jul   updated anthera pharmaceuticals provides additional data from the recently completed pearlsc study of blisibimod in the proposed phase  population hayward calif july   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today announced the final set of clinical data from the phase b pearlsc study in patients with systemic lupus erythematosus  pdf add to briefcase file is in briefcase jul   anthera pharmaceuticals to present at the th annual jmp securities healthcare conference hayward calif july   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today announced that paul f truex antheras president and chief executive officer will present the companys corporate overview o pdf add to briefcase file is in briefcase jun   anthera updates phase  plans following results from the phase b pearlsc dose ranging study of blisibimod hayward calif june   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today announced results from the phase b pearlsc clinical study in patients with systemic lupus erythematosus   the purp pdf add to briefcase file is in briefcase may   anthera pharmaceuticals reports  first quarter financial results and provides clinical progress update hayward calif may   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced financial results and business highlights for the quarter ended march   financial results total operating expenses for the first quarter ended march   were  million as compared to  million for the fou pdf add to briefcase file is in briefcase apr   anthera announces first quarter  financial report and conference call hayward calif april   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders will release its first quarter  financial report after market close on thursday may   anthera will host a conference c pdf add to briefcase file is in briefcase apr   anthera announces the completion of patient dosing in phase b pearlsc study hayward calif april   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today announced the completion of dosing in the companys phase b pearlsc study pearlsc a randomized doubleblind phase b s pdf add to briefcase file is in briefcase apr   anthera pharmaceuticals to present at the biocentury future leaders conference hayward calif april   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today announced that paul f truex antheras president and chief executive officer will provide a corporate presentation at the  pdf add to briefcase file is in briefcase mar   anthera provides corporate update on recent activities hayward calif march   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today provided an update on company events following the recent termination of the vista clinical study immediately af pdf add to briefcase file is in briefcase mar   anthera halts vista clinical study due to lack of efficacy following recommendation by the independent data safety monitoring board hayward calif march   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today announced that the vista data safety monitoring board dsmb has recommended stopping the vista clinical study due to a pdf add to briefcase file is in briefcase mar   dr bogdan dziurzynski joins anthera pharmaceuticals board of directors hayward calif march   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases including cardiovascular and autoimmune disorders today announced that it has appointed dr bogdan dziurzynski to its board of directors bogdans extensive global regulatory e pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals completes interim analysis of pearlsc clinical trial with blisibimod hayward calif march   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases including cardiovascular and autoimmune disorders today announced the continuation of the phase b pearlsc clinical study following an interim analysis of all safety and efficacy data pdf add to briefcase file is in briefcase feb   anthera pharmaceuticals to present at the citi global health care conference hayward calif feb   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today announced that paul f truex antheras president and chief executive officer will provide a corporate presentation at the c pdf add to briefcase file is in briefcase feb   anthera pharmaceuticals reports  fourth quarter financial results and provides clinical progress update hayward calif feb   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced financial results and business highlights for the quarter ended december   financial results total operating expenses for the fourth quarter ended december   were  million as compared to  million for the sa pdf add to briefcase file is in briefcase feb   anthera announces fourth quarter  financial report and conference call hayward calif feb   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation will release its fourth quarter  financial report before the market opens on tuesday february   anthera will host a conference call at  pm east pdf add to briefcase file is in briefcase dec   anthera announces completion of safety review by dsmb for vista hayward calif dec   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today announced that the vista data safety monitoring board dsmb has met for the fifth time to review available safety data an pdf add to briefcase file is in briefcase dec   anthera pharmaceuticals promotes dr debra odink to chief technology officer hayward calif dec   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing therapeutics to treat serious diseases associated with inflammation and autoimmune disorders today announced dr debra odink has been promoted to the role of chief technology officer and senior vice president  pdf add to briefcase file is in briefcase dec   anthera pharmaceuticals completes interim bcell analysis of pearlsc study hayward calif dec   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced positive interim biomarker data from the pearlsc phase b clinical study in patients with systemic lupus erythematosus after analysis by pdf add to briefcase file is in briefcase nov   anthera pharmaceuticals reports  third quarter financial results and operational update hayward calif nov   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced financial results and business highlights for the quarter ended september   financial results total operating expenses for the third quarter ended september   were  million as compared to  million for the sam pdf add to briefcase file is in briefcase oct   anthera announces last patient enrolled in pearlsc study hayward calif oct   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced it has completed enrollment in the phase b pearlsc study  pearlsc a randomized doubleblind phase b study to evaluate the efficacy s pdf add to briefcase file is in briefcase oct   anthera announces third quarter  financial report and conference call hayward calif oct   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced it will release its third quarter  financial report and provide an update on its development programs after market close on tuesday nov pdf add to briefcase file is in briefcase sep   anthera pharmaceuticals announces notice of allowance of us patent application covering a plus statin compositions hayward calif sept   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced that the us patent and trademark office has given the company a notice of allowance for us patent application no  entitled t pdf add to briefcase file is in briefcase jul   anthera pharmaceuticals reports  second quarter financial results and operational update hayward calif july   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced financial results and business highlights for the quarter ended june   financial results total operating expenses for the second quarter ended june   were  million as compared to  million for the same period pdf add to briefcase file is in briefcase jun   anthera pharmaceuticals announces completion of public offering of common stock hayward calif june   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced that it has completed the previously announced underwritten public offering of  shares of its common stock offered at a price of  per share  in addition the company has sold  shares of its common stock at a price of  pdf add to briefcase file is in briefcase jun   anthera pharmaceuticals announces pricing of public offering of common stock hayward calif june   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced the pricing of an underwritten public offering of  shares of its common stock offered at a price of  per share the offering is expected to close on or about june   subject to customary closing conditions in addition an pdf add to briefcase file is in briefcase jun   anthera pharmaceuticals announces proposed public offering of common stock hayward calif june   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced that it intends to offer and sell shares of its common stock in an underwritten public offering  the company expects to grant the underwriters a day option to purchase up to an additional  of the shares of common stock offered in the p pdf add to briefcase file is in briefcase may   anthera pharmaceuticals reports  first quarter financial results and operational update hayward calif may   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced financial results and business highlights for the quarter ended march   financial results total operating expenses for the first quarter ended march   were  million as compared to  million for the same period  pdf add to briefcase file is in briefcase apr   anthera pharmaceuticals successfully completes interim biomarker analysis of vista study and third safety review of varespladib methyl hayward calif april   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced that enrollment in the phase  vista study of varespladib in acute coronary syndromes acs will continue based on the positive outcome  pdf add to briefcase file is in briefcase feb   anthera pharmaceuticals to present at the citi  global health care conference hayward calif feb   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with abnormal autoimmune responses and inflammation today announced paul truex antheras president and chief executive officer will present at citis  global health ca pdf add to briefcase file is in briefcase feb   anthera announces conference call to discuss analytical method and timing of upcoming vista biomarker analysis hayward calif feb   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced it will hold a conference call to discuss the analytical method of the upcoming vista interim biomarker analysis and the expected timelin pdf add to briefcase file is in briefcase feb   anthera pharmaceuticals reports  fourth quarter and year end financial results and operational update hayward calif feb   prnewswire  anthera pharmaceuticals inc nasdaq anth today announced financial results and business highlights for the quarter and year ended december   financial results total operating expenses for the fourth quarter ended december   were  million as compared to  million fo pdf add to briefcase file is in briefcase feb   anthera pharmaceuticals names lawrence rosania as vice president of global regulatory affairs and compliance hayward calif feb   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with abnormal autoimmune responses and inflammation today announced that it has appointed lawrence rosania to the position of vice president of global regulatory affairs and  pdf add to briefcase file is in briefcase feb   dr peter thompson joins anthera pharmaceuticals board of directors hayward calif feb   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with abnormal autoimmune responses and inflammation today announced that it has appointed dr peter thompson to its board of directors currently dr thompson is a venture p pdf add to briefcase file is in briefcase jan   anthera pharmaceuticals to present at the th annual jp morgan healthcare conference hayward calif jan   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced paul f truex antheras president and chief executive officer will present at the th annual jp morgan healthcare conference in san fran pdf add to briefcase file is in briefcase dec   anthera pharmaceuticals selects the merck biomanufacturing network as manufacturing supplier for a antheras investigational novel peptibody agent hayward calif dec   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with abnormal autoimmune responses and inflammation has selected the merck biomanufacturing network in the uk to manufacture the large scale gmp clinical and precommercial pdf add to briefcase file is in briefcase dec   anthera announces update call regarding vial problems hayward calif dec   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced it will hold a conference call to provide an update on the ongoing investigation and remediation plans relating to vial problems in the pearl pdf add to briefcase file is in briefcase dec   varespladib receives  european society pediatric research award hayward calif dec   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced that their product candidate varespladib a was awarded the  european society pediatric research award at the third congress of the  pdf add to briefcase file is in briefcase dec   anthera pharmaceuticals to present at the th annual canaccord genuity cardiovascular diabetes  obesity conference hayward calif dec   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced paul f truex antheras president and chief executive officer will present at the th annual canaccord genuity cardiovascular diabetes  o pdf add to briefcase file is in briefcase nov   anthera pharmaceuticals to present at the nd annual piper jaffray health care conference hayward calif nov   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced paul f truex antheras president and chief executive officer will present at the nd annual piper jaffray health care conference in new  pdf add to briefcase file is in briefcase nov   anthera suspends enrollment and dosing in pearlsc clinical trial to address reports of vial problems hayward calif nov   prnewswirefirstcall  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced that it has notified the us food and drug administration fda that the company has placed a voluntary hold on pearlsc the phase pdf add to briefcase file is in briefcase nov   anthera pharmaceuticals to present at american heart associations  scientific sessions hayward calif nov   prnewswire  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced the abstract entitled antiinflammatory effects of varespladib in diabetic patients with acute coronary syndromes will be presented at the pdf add to briefcase file is in briefcase nov   anthera pharmaceuticals reports  third quarter financial results and operational update hayward calif nov   prnewswire via comtex news network  anthera pharmaceuticals inc nasdaq anth today announced financial results and business highlights for the third quarter ended september   financial results total operating expenses for the third quarter ended september   were  million as compared to  pdf add to briefcase file is in briefcase oct   anthera announces third quarter  financial report and conference call hayward calif oct   prnewswire via comtex news network  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced it will release its third quarter  financial report after market close on tuesday november   anthera wil pdf add to briefcase file is in briefcase sep   anthera pharmaceuticals announces pricing of  million pipe financing hayward calif sept   prnewswire via comtex news network  anthera pharmaceuticals inc nasdaq anth today announced that it has entered into definitive agreements with certain accredited investors in connection with a private placement or pipe financing transaction pursuant to section  of the securities act of  as amende pdf add to briefcase file is in briefcase aug   anthera pharmaceuticals reports  second quarter results hayward calif aug   prnewswire via comtex news network  anthera pharmaceuticals inc nasdaq anth today announced financial results and business highlights for the second quarter ended june   financial results total operating expenses for the second quarter ended june   were  million as compared to  mill pdf add to briefcase file is in briefcase jul   anthera initiates expanded and extended pearlsc phase b clinical study in lupus with a  a subcutaneous dual inhibitor of membrane and soluble bcell activating factor baff or blys hayward calif july   prnewswire via comtex news network  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced it has initiated pearlsc the phase b study of a a novel inhibitor of bcell activating factor or baff for  pdf add to briefcase file is in briefcase jul   anthera announces second quarter  financial report and conference call hayward calif july   prnewswire via comtex news network  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced it will release its second quarter  financial report after market close on wednesday august   anthera wi pdf add to briefcase file is in briefcase jun   anthera enrolls first patients in pivotal varespladib phase  clinical study hayward calif june   prnewswire via comtex news network  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders today announced patient enrollment has commenced in the companys pivotal vista vascular inflammation s pdf add to briefcase file is in briefcase jun   anthera pharmaceuticals updates its lupus scientific advisory board hayward calif june   prnewswire via comtex news network  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing therapeutics to treat serious diseases associated with inflammation and autoimmune disorders today announced it has updated its lupus scientific advisory board a is antheras phase b com pdf add to briefcase file is in briefcase jun   anthera pharmaceuticals promotes colin hislop md to chief medical officer hayward calif june   prnewswire via comtex news network  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing therapeutics to treat serious diseases associated with inflammation and autoimmune disorders today announced colin hislop md has been promoted to the role of chief medical officer of anthera pdf add to briefcase file is in briefcase may   anthera issues first quarter  financial report hayward calif may   prnewswire via comtex news network  anthera pharmaceuticals inc nasdaq anth today issued its first quarter  financial report financial results total operating expenses for the first quarter ended march   were  million as compared to  million for the same period in  the increase in  pdf add to briefcase file is in briefcase may   anthera pharmaceuticals announces additional data from francis study hayward calif may   prnewswire via comtex news network  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced detailed results from a new biomarker analysis of the francis study francis examined the effects of oncedaily vares pdf add to briefcase file is in briefcase apr   anthera announces first quarter  financial report and conference call hayward calif april   prnewswire via comtex news network  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced it will release its first quarter  financial report after market close on thursday may   anthera will  pdf add to briefcase file is in briefcase apr   anthera pharmaceuticals to present at deutsche bank securities th annual health care conference hayward calif april   prnewswire via comtex news network  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced paul f truex antheras president and chief executive officer will present at the deutsche bank th annual health pdf add to briefcase file is in briefcase apr   anthera pharmaceuticals announces closing of underwriters exercise of overallotment option in connection with its initial public offering hayward calif april   prnewswire via comtex news network  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced the closing of the underwriters exercise of their overallotment option to purchase an additional  shares of pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals welcomes georgina kilfoil as senior vice president of product development and clinical operations hayward calif march   prnewswire via comtex news network  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced it has hired georgina kilfoil to the newly created position of senior vice president of product development and cli pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals completes initial public offering hayward calif march   prnewswire via comtex news network  anthera pharmaceuticals inc nasdaq anth a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation today announced the completion of its initial public offering of six million shares of common stock at a price of  per share  pdf add to briefcase file is in briefcase feb   anthera pharmaceuticals announces agreement with the fda on a spa for planned phase  varespladib a study daniel k spiegelman joins board of directors hayward ca – february   – anthera pharmaceuticals inc a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation announced today that it reached an agreement with the us food and drug administration fda on a special protocol assessmen pdf add to briefcase file is in briefcase may   antheras varespladib meets primary endpoint in phase  francis trial for the treatment of acute coronary syndrome hayward ca – may   – anthera pharmaceuticals inc a privately held biopharmaceutical company developing antiinflammatory drugs announced today that francis fewer recurrent acute coronary events with nearterm cardiovascular inflammation suppression a clinical trial designed to examine the impact of mg  pdf add to briefcase file is in briefcase mar   following encouraging results anthera to continue impacts trial for the prevention of acute chest syndrome in patients with sickle cell disease hayward ca – march   – anthera pharmaceuticals inc a privately held biopharmaceutical company developing antiinflammatory drugs announced today that after completing its review of safety and efficacy data from the first cohort of  patients an independent data safety monitoring board dsmb has recommend pdf add to briefcase file is in briefcase jan   anthera announces enrollment of th patient in francis trial of a for the treatment of cardiovascular disease hayward ca – january   – anthera pharmaceuticals inc a privatelyheld biopharmaceutical company developing antiinflammatory drugs announced today the enrollment of its th patient in its francis fewer recurrent acute coronary events with nearterm cardiovascular inflammation suppression clin pdf add to briefcase file is in briefcase nov   antheras varespladib demonstrates significant antiinflammatory effect and ldl reduction in patients with coronary heart disease hayward ca – november ‚  – anthera pharmaceuticals inc a privately held biopharmaceutical company developing antiinflammatory drugs today announced new data on its lead product varespladib a at the american heart association aha annual conference in new orleans louisiana anthera has complet pdf add to briefcase file is in briefcase aug   anthera pharmaceuticals advances global development strategy for varespladib in patients with acute coronary syndrome with the initiation of francis trial san mateo ca – august   – anthera pharmaceuticals inc a privately held biopharmaceutical company developing antiinflammatory drugs today announced the initiation of the francis fewer recurrent acute coronary events with nearterm cardiovascular inflammation suppression clinical trial designed to examine th pdf add to briefcase file is in briefcase aug   anthera pharmaceuticals completes  million financing appoints christopher s henney as chairman san mateo ca – august   – anthera pharmaceuticals inc a privately held biopharmaceutical company developing antiinflammatory drugs today announced the completion of a  million equity financing new investors caxton advantage life sciences fund new york ny and hbm biocapital cayman islands led the fi pdf add to briefcase file is in briefcase apr   anthera presents data on varespladib at atvb meeting san mateo ca – april   – anthera pharmaceuticals inc a privately held biopharmaceutical company developing antiinflammatory drugs announced today that anthera scientists and collaborators have released data from the varespladib a clinical and preclinical programs at the arteriosclerosis thrombosis  pdf add to briefcase file is in briefcase apr   dsmb supports continuation of anthera phase ii impacts trial for the prevention of acute chest syndrome in patients with sickle cell disease san mateo ca – april   – anthera pharmaceuticals inc a privately held biopharmaceutical company developing antiinflammatory drugs announced today that after completing its review of safety and efficacy data currently available an independent data safety monitoring board dsmb has recommended that anthera pdf add to briefcase file is in briefcase feb   data from antheras plasma trial to be presented as late breaker at american college of cardiology scientific sessions san mateo ca – february   – anthera pharmaceuticals inc a privately held biopharmaceutical company developing antiinflammatory drugs announced today that data from the phase ii trial of its novel secretory phospholipasea inhibitor varespladib a for the treatment of coronary heart disease will be prese pdf add to briefcase file is in briefcase jan   anthera enters into manufacturing agreements for varespladib in preparation for pivotal phase iii trials san mateo california  january    anthera pharmaceuticals inc today announced it has entered into manufacturing agreements with albemarle corporation and patheon inc the agreements provide for the largescale clinical production of varespladib a which is expected to be necessary in preparation for anthera’s pdf add to briefcase file is in briefcase jan   anthera announces preliminary positive results from oncedaily a phase ii cardiovascular trial san mateo ca – january   – anthera pharmaceuticals inc a privatelyheld biopharmaceutical company reported preliminary results of a second phase iib clinical trial of a for the treatment of cardiovascular disease in this second study administration of oncedaily a lowered both  pdf add to briefcase file is in briefcase jan   anthera pharmaceuticals acquires the worldwide rights to a baff inhibitor for the treatment of lupus and other autoimmune diseases san mateo ca – january   – anthera pharmaceuticals inc a privatelyheld drug development company announced today that it has entered into a license agreement with amgen inc for the exclusive and worldwide rights to develop and commercialize amg  a peptide fusion protein for the treatment of systemic lup pdf add to briefcase file is in briefcase dec   antheras a receives orphan drug status for the prevention of acute chest syndrome in patients with sickle cell disease san mateo ca – december   – anthera pharmaceuticals inc a privately held biopharmaceutical company developing antiinflammatory drugs announced today that the us food and drug administration fda office of orphan product development has granted a orphan drug status for the prevention of acute chest pdf add to briefcase file is in briefcase dec   anthera pharmaceuticals names christopher p lowe chief financial officer san mateo ca  december    anthera pharmaceuticals inc a privately held biopharmaceutical company developing antiinflammatory drugs for chronic and acute diseases announced today the appointment of christopher p lowe to the position of vice president of administration and chief financial officer mr lowe will be r pdf add to briefcase file is in briefcase oct   anthera pharmaceuticals inc appoints donald santel to board of directors san mateo ca  october    anthera pharmaceuticals inc a privately held biopharmaceutical company developing antiinflammatory drugs for chronic and acute diseases today announced that donald j santel has been appointed to anthera’s board of directors “don’s experience in transfor pdf add to briefcase file is in briefcase oct   anthera announces positive phase ii clinical results from a cardiovascular disease trial san mateo ca  october    anthera pharmaceuticals inc a privatelyheld biopharmaceutical company reported results of a phase ii clinical trial of its first compound a for the treatment of cardiovascular disease the trial results suggest that treatment with a resulted in significant reductions in blood lev pdf add to briefcase file is in briefcase oct   anthera announces completion of enrollment and dosing in phase ii trial of a for the treatment of cardiovascular disease san francisco‚ ca – october ‚  – anthera pharmaceuticals inc a privatelyheld biopharmaceutical company developing antiinflammatory therapeutics for chronic and acute inflammatory diseases announced today the completion of enrollment and patient dosing in its phase ii clinical study of its lead com pdf add to briefcase file is in briefcase jul   anthera completes enrollment of plasma trial with a and announces initiation of new investigator study san mateo ca  july    anthera pharmaceuticals inc a privately held biopharmaceutical company developing antiinflammatory drugs for chronic and acute diseases announced today that enrollment of  patients in the phase  plasma phospholipase levels and serological markers of ath pdf add to briefcase file is in briefcase apr   first patient enrolled in phase  plasma trial with a for patients with coronary atherosclerosis san mateo ca  april    anthera pharmaceuticals inc a privately held biopharmaceutical company developing antiinflammatory drugs for chronic and acute diseases announced today that enrollment has begun in the companys multicenter phase  clinical trial plasma  phospholipase levels a pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals inc announces appointment of dr james pennington as executive vice president  chief medical officer san mateo‚ ca – march ‚  – anthera pharmaceuticals inc a privately held biopharmaceutical company developing antiinflammatory drugs for chronic and acute diseases announced today the appointment of james e pennington md to the position of executive vice president  chief medical officer dr pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals inc announces formation of clinical advisory board for respiratory and acute care programs san mateo‚ ca – march ‚  – anthera pharmaceuticals inc a privately held biopharmaceutical company developing antiinflammatory drugs for acute and chronic diseases announced today the appointment of drs alan leff michael a matthay b taylor thompson and stephen rennard to its respiratory and acu pdf add to briefcase file is in briefcase feb   anthera pharmaceuticals inc announces formation of clinical advisory board for cardiovascular program san mateo‚ ca – february ‚  – anthera pharmaceuticals‚ inc‚ a privately held biopharmaceutical company developing anti–inflammatory drugs for chronic and acute diseases‚ announced today the appointment of dr david waters‚ dr robert rosenson and dr stephen nicholls to its card pdf add to briefcase file is in briefcase feb   dr david d waters joins anthera pharmaceuticals as cardiovascular research fellow san mateo‚ ca – february ‚  – anthera pharmaceuticals inc a privately held biopharmaceutical company developing antiinflammatory drugs for chronic and acute diseases announced today that david d waters md has joined the company as cardiovascular research fellow dr waters has over  years of exp pdf add to briefcase file is in briefcase jan   anthera receives ind approval from fda to begin phase  impacts trial with a for prevention of acute chest syndrome in patients with sickle cell disease san mateo‚ ca – january ‚  – anthera pharmaceuticals‚ inc‚ a privately held biopharmaceutical company developing antiinflammatory drugs‚ announced today that the us food and drug administration has approved its investigational new drug ind application for use of its lead compound a pdf add to briefcase file is in briefcase jan   anthera receives fda approval to begin phase  plasma trial with a for patients with coronary atherosclerosis san mateo‚ ca – january ‚  – anthera pharmaceuticals‚ inc‚ a privately held biopharmaceutical company developing antiinflammatory drugs for chronic and acute diseases‚ announced today that the us food and drug administration has approved its investigational new drug ind application  pdf add to briefcase file is in briefcase dec   anthera employee keiko mitsunobu finishes honolulu marathon in successful effort to raise money for childrens hospital oakland research institute san mateo‚ ca – december ‚  – after months of hard training combined with an extraordinary personal effort to raise money for children’s hospital oakland research institute chori keiko mitsunobu senior director of business development at anthera pharmaceuticals finished the honolulu marathon pdf add to briefcase file is in briefcase sep   anthera pharmaceuticals secures m venture financing to initiate clinical programs san francisco‚ ca – september ‚  – anthera pharmaceuticals‚ a specialty pharmaceutical company developing therapies for the treatment of serious inflammatory diseases‚ today announced it closed an initial  million in venture financing the funding was co–led by vantagepoint venture  pdf add to briefcase file is in briefcase sep   anthera licenses portfolio of antiinflammatory products from eli lilly and company and shionogi  co ltd san francisco‚ ca – september ‚  anthera pharmaceuticals inc a privately held biopharmaceutical company developing antiinflammatory drugs announced today that it has entered into a license agreement with eli lilly and company and shionogi  co ltd under which anthera has obtained worldwide except  pdf add to briefcase file is in briefcase nov   anthera pharmaceuticals appoints david e thompson to board of directors san francisco‚ ca – november ‚  – anthera pharmaceuticals‚ inc‚ a private start–up pharmaceutical company committed to addressing the unmet medical needs of patients with life–threatening inflammatory diseases‚ announced that david e thompson has been appointed to the co pdf add to briefcase file is in briefcase apr   anthera pharmaceuticals launches with a proven leadership team and significant series a funding san francisco‚ ca – april ‚  – anthera pharmaceuticals‚ inc‚ a private start–up pharmaceutical company specializing in serious respiratory and inflammatory diseases‚ today announced it has completed its series a preferred financing and is moving forward under a proven leadership  pdf add to briefcase file is in briefcase  add release to briefcase corporate profile events  presentations press releases analyst coverage stock information corporate governance financials  filings investor contact facebook google linkedin twitter email rss anthera pharmaceuticals  wikipedia anthera pharmaceuticals from wikipedia the free encyclopedia   redirected from anthera pharmaceuticals inc jump to navigation search a major contributor to this article appears to have a close connection with its subject it may require cleanup to comply with wikipedias content policies particularly neutral point of view please discuss further on the talk page january  learn how and when to remove this template message anthera pharmaceuticals inc type public traded as nasdaq anth industry pharmaceuticals founded  headquarters hayward california us key people craig thompson president and ceo website antheracom anthera pharmaceuticals inc is a biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis inflammation and autoimmune diseases liprotamase sollpura anthera’s leading drug candidate which is being developed for exocrine pancreatic insufficiency epi is currently in phase  clinical trials and a blisibimod for the treatment of iga nephropathy is currently in phase  clinical trial contents  products  blisibimod  sollpura  references  external links productsedit blisibimodedit blisibimod is a selective peptibody antagonist of bcell activating factor baff baff is critical to the development maintenance and survival of bcells but is known to be upregulated in autoimmune diseases it is primarily expressed by macrophages monocytes and dendritic cells blisibimod binds to baff and inhibits the interaction of baff with its receptors blisibimod is currently being evaluated in iga nephropathy  sollpuraedit july  anthera acquired sollpura liprotamase from eli lilly and company sollpura is an investigational pancreatic enzyme replacement therapy pert that uses three biotechnologyderived digestive enzymes intended to treat patients with endocrine pancreatic insufficiency as a result of cystic fibrosis and other diseases referencesedit  overview anthera pharmaceuticalsinc archived from the original on august   retrieved august     management team anthera pharmaceuticals inc anthera pharmaceuticals inc retrieved august     groom j kalled sl cutler ah olson c woodcock sa schneider p tschopp j cachero tg batten m wheway j mauri d cavill d gordon tp mackay cr mackay f jan  association of baffblys overexpression and altered b cell differentiation with sjögrens syndrome j clin invest   – pmc   pmid  doijci   petri michelle stohl william chatham winn mccune joseph chevrier marc ryel jeff recta virginia zhong john freimuth william arthritis  rheumatism vol  no  august  pp – doi art   american college of rheumatology association of plasma b lymphocyte stimulator levels and disease activity in systemic lupus erythematosus pdf deepblue american college of rheumatology retrieved august     zhang j roschke k baker kp wang z alarcon gs fessler bj bastian h kimberly rp zhou t  cutting edge a role for b lymphocyte stimulator in systemic lupus erythematosus journal of immunology baltimore md   j immunol   – pmid  doijimmunol   product candidates anthera pharmaceuticals inc anthera pharmaceuticals inc archived from the original on august   retrieved august     hsu h khare sd lee f miner k hu yl stolina m hawkins n chen q ho sy min h xiong f boone t zack dj a novel modality of baffspecific inhibitor amg peptibody reduces bcell number and improves outcomes in murine models of autoimmune disease clin exp rheumatol clinical and experimentla rheumatology   – pmid    anthera pharmaceuticals announces acquisition of sollpura® liprotamase for exocrine pancreatic insufficiency from eli lilly and company anthera pharmaceuticals inc anthera pharmaceuticals retrieved august     anthera pharmaceuticals announces acquisition of sollpura® liprotamase for exocrine pancreatic insufficiency from eli lilly and company anthera pharmaceuticals inc anthera pharmaceuticals retrieved august    external linksedit california portal companies portal official website   v t e pharmaceutical companies of the united states current abbott laboratories acorda therapeutics aderis pharmaceuticals advaxis alcon alexion pharmaceuticals alkermes allergan amgen avax technologies baxter international biocryst pharmaceuticals biogen bioverativ biovest biovista bristolmyers squibb century pharmaceuticals ceragenix pharmaceuticals combe incorporated cortex pharmaceuticals cytosport cytrx danco laboratories eli lilly and company elorac endo pharmaceuticals par pharmaceutical galena biopharma genvec genentech gilead sciences institute for oneworld health intercept pharmaceuticals johnson  johnson ethicon janssen biotech mcneil consumer healthcare orthomcneil pharmaceutical kinetic concepts mallinckrodt mckesson corporation melinta therapeutics formerly ribx pharmaceuticals melior discovery mentholatum merck  co mylan myriad genetics northwest biotherapeutics norwich pharma services novabay pharmaceuticals ovation pharmaceuticals perrigo pfizer hospira searle pharmaceutical product development prasco laboratories procter  gamble proteon therapeutics purdue pharma quark pharmaceuticals regeneron repros therapeutics sarepta therapeutics savage laboratories sheffield pharmaceuticals spectrum pharmaceuticals tec laboratories teva pharmaceutical industries actavis tapi tiens biotech group titan pharmaceuticals trevena inc upshersmith laboratories valeant pharmaceuticals bausch  lomb ventria bioscience vertex pharmaceuticals west pharmaceutical services former alza amylin pharmaceuticals ariad pharmaceuticals biolex bradley pharmaceuticals cancervax cephalon cotherix covance covidien cubist pharmaceuticals cutter laboratories dnaprint genomics epix pharmaceuticals forest laboratories genta imclone systems ista pharmaceuticals king pharmaceuticals kv pharmaceutical leiner health products martek biosciences corporation s e massengill company miles laboratories naurex nereus pharmaceuticals nuvelo organon international ortho pharmaceutical osi pharmaceuticals parkedavis qualitest scheringplough smith kline  french sterling drug tanox tap pharmaceutical products trubion upjohn verus pharmaceuticals vion pharmaceuticals inc viropharma wyeth zonite products corporation list of pharmaceutical companies retrieved from httpsenwikipediaorgwindexphptitleantherapharmaceuticalsoldid categories pharmaceutical companies of the united statescompanies based in hayward californiatechnology companies based in the san francisco bay areahealth care companies based in californiahidden categories wikipedia articles with possible conflicts of interest from january pages using deprecated image syntax navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages add links this page was last edited on  july  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view blisibimod – anthera pharmaceuticals phone infoantheracom blisibimod siteadministrator t blisibimod blisibimod was licensed from amgen in december  with exclusive worldwide rights  blisibimod targets bcell activating factor or baff which has been shown to be elevated in a variety of bcell mediated autoimmune diseases including immunoglobulin a nephropathy or iga nephropathy systemic lupus erythematosus or lupus lupus nephritis and others blisibimod is currently in development for the treatment of iga nephropathy igan  igan also known as berger’s disease is the most common cause of primary glomerulonephritis worldwide occurring more frequently in asia than in europe or north america igan is characterized by deposition of igaanti iga immune complexes in the kidney resulting in inflammation the leakage of blood and protein into the urine and loss of kidney function the disease typically progresses slowly but as many as  of adults will eventually develop endstagerenal disease and require dialysis or kidney transplant  there are currently no approved therapies for iga nephropathy anthera is currently conducting one study with blisibimod bright•sc the primary objective of this study is to evaluate the clinical efficacy of blisibimod as a treatment for iga nephropathy learn more pipelinesollpura blisibimod publications anth stock price  anthera pharmaceuticals inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers ctas  cof  etfc  syf  hp  isrg  hban  chk  latest newsall times eastern p updated ‘game of thrones’ the four biggest takeaways from stormborn’ p updated why you’re more likely to die in an accident during the summer months p updated these wealthy parents spend  for summer camps so their kids can be ‘normal’ p updated  totally avoidable reasons why millennials can’t have nice things or save any money p updated how elon musk and shorter commutes could transform people’s lives p updated john mccain is a war hero — but think twice before saying he’s ‘battling’ cancer p updated the dark side of cruises p updated at least  dead after overheated tractortrailer found outside texas walmart p ‘full transparency’ doesn’t mean what scaramucci apparently thinks it means p stocks brace for volatility in earnings deluge fed meeting looms to be replaced home investing quotes stocks united states anth overview compare quotes stock screener earnings calendar sectors nasdaq anth us nasdaq join td ameritrade find a broker anthera pharmaceuticals inc watchlist createanthalert closed last updated jul    pm edt delayed quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee na pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones anthera pharmaceuticals downgraded at suntrust price target slashed to  from  dec   at  am et by ciara linnane anthera pharmaceuticals downgraded to hold vs buy at suntrust robinson humphrey dec   at  am et by ciara linnane anthera pharmaceuticals stock price target slashed to  vs  at suntrust robinson dec   at  am et by ciara linnane anthera pharma plunges  after missing target in study dec   at  pm et by jeremy c owens anthera pharma stock rises  on safety review boards goahead for latestage drug trial aug   at  am et by emma court dow industrials teeter on major technical support aug   at  pm et by michael ashbaugh alcoa shares rise slightly as revenue tops estimates jul   at  pm et by wallace witkowski  stocks to watch jun   at  pm et by harry boxer  cheapest stocks in the nasdaq’s hottest sector feb   at  am et by philip van doorn  stocks that are pushing the nasdaq to  feb   at  pm et by philip van doorn stock futures edge up after retail claims data dec   at  am et by victor reklaitis stocks to watch thursday libbey jm smucker jul   at  am et by marketwatch anthera cut to sell by citigroup jun   at  am et by greg morcroft thursday’s top gaining and declining stocks jun   at  pm et by marketwatch anthera plunges on drug study jun   at  am et by val brickates kennedy stocks to watch friday ups ak steel amerigas mar   at  am et by marketwatch monday’s biggest gaining and declining stocks mar   at  pm et by kate gibson anthera plunges  on failed study mar   at  am et by val brickates kennedy us stock futures fall before euroarea meeting mar   at  am et by barbara kollmeyer stocks to watch monday cocacola michael kors mar   at  am et by marketwatch clinical development news jan  jan   at  pm et on the wall street journal stocks to watch anthera pharma galena biopharma delta air dec   at  am et on the wall street journal the fundamental reason stocks could keep heading higher in  dec   at  am et on the wall street journal cfo moves anthem cornerstone ondemand may   at  pm et on the wall street journal stocks to watch oshkosh hasbro tempurpedic jan   at  am et on the wall street journal stocks to watch morgan stanley walgreen ebay jul   at  am et on the wall street journal tahoe resources anthera pharmaceuticals biggest price decliners taho anth jun   at  pm et on the wall street journal stocks to watch family dollar stores aol synergetics jun   at  am et on the wall street journal stocks to watch cogo perfect world anthera and more mar   at  am et on the wall street journal stocks to watch cogo perfect world anthera and more mar   at  am et on the wall street journal dow posts fourth straight gain mar   at  pm et on the wall street journal mcewen mining anthera pharmaceuticals biggest price decliners mux anth mar   at  pm et on the wall street journal verso paper anthera pharmaceuticals biggest price decliners vrs anth mar   at  pm et on the wall street journal stocks to watch zoll medical pacific capital youku mar   at  am et on the wall street journal china new borun anthera pharmaceuticals biggest price gainers born anth oct   at  pm et on the wall street journal companies turn to reverse stock splits ahead of ipos sep   at  pm et on the wall street journal bluelinx holdings anthera pharmaceuticals biggest price gainers bxc anth sep   at  pm et on the wall street journal steelcase anthera pharmaceuticals biggest price gainers scs anth sep   at  pm et on the wall street journal after a half century of work medicine for lupus may be near jun   at  pm et on the wall street journal first bancorp puerto rico anthera pharmaceuticals biggest price gainers fbp anth apr   at  pm et on the wall street journal recent news other news press releases anthera pharma to be opportunistic with capital raising anthera pharma to be opportunistic with capital raising jun   at  pm et on seeking alpha anthera continues down move shares off  anthera continues down move shares off  may   at  am et on seeking alpha axovant sciences axon shows strength stock jumps  apr   at  am et on zackscom anths anth blisibimod completes dosing in phase iii study apr   at  am et on zackscom should you get rid of aimmune therapeutics aimt now apr   at  am et on zackscom biotelemetry beat shows strength stock moves  higher apr   at  am et on zackscom cellect biotechnology apop jumps stock moves  higher apr   at  am et on zackscom bill ackman apologizes for valeant investment error mar   at  pm et on zackscom antheras sollpura on par with pancreaze in extension phase of latestage study in certain cf patients shares ahead  after hours mar   at  pm et on seeking alpha cara therapeutics cara shows strength stock up  mar   at  am et on zackscom will endos troubles continue to dent performance in  mar   at  pm et on zackscom astrazenecas lung cancer drug tagrisso approved in china mar   at  am et on zackscom merrimack mack starts enrollment in solid tumors study mar   at  pm et on zackscom shire shpg rare disease drug gets fast track designation mar   at  pm et on zackscom ovascience inc ovas looks good stock up  higher mar   at  am et on zackscom enzo biochem inc enz shows strength stock up  mar   at  am et on zackscom avexis inc avxs looks good stock moves  higher mar   at  am et on zackscom fortress biotech fbio catches eye stock moves up  mar   at  am et on zackscom valeant vrx shares up on valueacts  stake increase mar   at  pm et on zackscom implied volatility surging for anthera anth stock options mar   at  am et on zackscom anthera pharmaceuticals announces result phase  clinical study of sollpura will be included in the cystic fibrosis foundation therapeutics development network anthera pharmaceuticals announces result phase  clinical study of sollpura will be included in the cystic fibrosis foundation therapeutics development network jul   at  am et on globenewswire research reports coverage on biotech stocks  anthera pharma cara therapeutics cerus and concert pharma research reports coverage on biotech stocks  anthera pharma cara therapeutics cerus and concert pharma jun   at  am et on pr newswire  prf anthera pharmaceuticals provides business update and reports  first quarter financial results anthera pharmaceuticals provides business update and reports  first quarter financial results may   at  pm et on globenewswire anthera pharmaceuticals announces for reverse split of stock anthera pharmaceuticals announces for reverse split of stock apr   at  pm et on globenewswire anth shareholder alert the law offices of vincent wong reminds investors of commencement of a class action involving anthera pharmaceuticals inc and a lead plaintiff deadline of april   apr   at  am et on accesswire anthera announces completion of dosing in the phase  brightsc study of blisibimod in patients with iga nephropathy apr   at  am et on globenewswire deadline alert brower piven reminds investors of the upcoming deadline in class action lawsuit and encourages investors with losses in excess of  from investment in anthera pharmaceuticals inc to contact the firm apr   at  pm et on businesswire  bzx research reports initiation on biotech stocks  sarepta therapeutics galena biopharma anthera pharma and clovis oncology apr   at  am et on pr newswire  prf anthera announces positive results from the extension period of the solution study of sollpura mar   at  pm et on globenewswire shareholder alert brower piven encourages investors who have losses in excess of  from investment in anthera pharmaceuticals inc anth to contact brower piven before the lead plaintiff deadline in class action lawsuit mar   at  pm et on globenewswire anth shareholder alert the law offices of vincent wong reminds investors of a class action involving anthera pharmaceuticals inc and a lead plaintiff deadline of april   mar   at  am et on globenewswire anthera pharmaceuticals announces pricing of  million public offering of common stock and warrants mar   at  am et on globenewswire anthera pharmaceuticals announces proposed public offering of common stock and warrants mar   at  pm et on globenewswire shareholder alert levi  korsinsky llp reminds investors it has filed a complaint to recover losses suffered by investors in anthera pharmaceuticals inc mar   at  am et on globenewswire anthera pharmaceuticals provides business update and reports  fourth quarter and fiscal year financial results feb   at  pm et on globenewswire research reports coverage on biotech stocks  anthera pharma arrowhead pharma pacific biosciences of california and conatus pharma feb   at  am et on pr newswire  prf shareholder alert brower piven notifies investors of class action lawsuit and encourages those who have losses in excess of  from investment in anthera pharmaceuticals inc anth to contact brower piven before the lead plaintiff deadline feb   at  pm et on globenewswire johnson  weaver llp announces investigations of clovis oncology inc usana health sciences inc anthera pharmaceuticals inc and pixarbio corporation feb   at  pm et on pr newswire  prf robbins arroyo llp anthera pharmaceuticals inc anth misled shareholders according to a recently filed class action feb   at  pm et on businesswire  bzx shareholder alert levi  korsinsky llp has filed a complaint to recover losses suffered by investors in anthera pharmaceuticals inc feb   at  am et on globenewswire anthera pharmaceuticals inc anthera pharmaceuticals inc is a biopharmaceutical company which focuses on developing and commercializing products to treat serious and lifethreatening diseases including lupus lupus with glomerulonephritis iga nephropathy and exocrine pancreatic insufficiency due to cystic fibrosis it develops phase  product candidates which includes blisibimod and liprotamase anthera pharmaceuticals was founded by paul f truex on september   and is headquartered in hayward ca see full profile analyst ratings sell under hold over buy number of ratings  full ratings benzingas top initiations jul   at  am et on benzingacom the top  wall street analysts of  dec   at  am et on benzingacom in the sea of biotechs antheras multidrug pipeline makes it attractive sep   at  am et on benzingacom partner content trending tickers powered by bzun  gbtc  googl  mrk  nyt  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience stocks index  markets index bulletin investor alert tokyo markets close in currencies europe markets london markets stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo open marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest p‘game of thrones’ the four biggest takeaways from stormborn’ pwhy you’re more likely to die in an accident during the summer months pthese wealthy parents spend  for summer camps so their kids can be ‘normal’ p totally avoidable reasons why millennials can’t have nice things or save any money phow elon musk and shorter commutes could transform people’s lives pjohn mccain is a war hero — but think twice before saying he’s ‘battling’ cancer pthe dark side of cruises pat least  dead after overheated tractortrailer found outside texas walmart p‘full transparency’ doesn’t mean what scaramucci apparently thinks it means pstocks brace for volatility in earnings deluge fed meeting looms pif you suddenly quit your job like sean spicer here’s what you should do next pnever ever say these things to a coworker pmy uncle with dementia needs longterm care — should i refinance his house pthis is the deadliest time of your life to put on weight pwhy house prices in gay neighborhoods are soaring pnearly  of adults don’t have life insurance — these startups are trying to change that pmarie kondo says this one thing could be holding you back from falling in love pthis luxury credit card is only for truly big spenders pbanks have raised creditcard interest rates — but not savings account rates aheavy showers swamp new orleans street with rainwater loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stocks index  markets index bulletin investor alert tokyo markets close in currencies europe markets london markets stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo open marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest p‘game of thrones’ the four biggest takeaways from stormborn’ pwhy you’re more likely to die in an accident during the summer months pthese wealthy parents spend  for summer camps so their kids can be ‘normal’ p totally avoidable reasons why millennials can’t have nice things or save any money phow elon musk and shorter commutes could transform people’s lives pjohn mccain is a war hero — but think twice before saying he’s ‘battling’ cancer pthe dark side of cruises pat least  dead after overheated tractortrailer found outside texas walmart p‘full transparency’ doesn’t mean what scaramucci apparently thinks it means pstocks brace for volatility in earnings deluge fed meeting looms pif you suddenly quit your job like sean spicer here’s what you should do next pnever ever say these things to a coworker pmy uncle with dementia needs longterm care — should i refinance his house pthis is the deadliest time of your life to put on weight pwhy house prices in gay neighborhoods are soaring pnearly  of adults don’t have life insurance — these startups are trying to change that pmarie kondo says this one thing could be holding you back from falling in love pthis luxury credit card is only for truly big spenders pbanks have raised creditcard interest rates — but not savings account rates aheavy showers swamp new orleans street with rainwater loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stockscountryunited states index  markets index bulletin investor alert tokyo markets close in currencies europe markets london markets stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo open marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest p‘game of thrones’ the four biggest takeaways from stormborn’ pwhy you’re more likely to die in an accident during the summer months pthese wealthy parents spend  for summer camps so their kids can be ‘normal’ p totally avoidable reasons why millennials can’t have nice things or save any money phow elon musk and shorter commutes could transform people’s lives pjohn mccain is a war hero — but think twice before saying he’s ‘battling’ cancer pthe dark side of cruises pat least  dead after overheated tractortrailer found outside texas walmart p‘full transparency’ doesn’t mean what scaramucci apparently thinks it means pstocks brace for volatility in earnings deluge fed meeting looms pif you suddenly quit your job like sean spicer here’s what you should do next pnever ever say these things to a coworker pmy uncle with dementia needs longterm care — should i refinance his house pthis is the deadliest time of your life to put on weight pwhy house prices in gay neighborhoods are soaring pnearly  of adults don’t have life insurance — these startups are trying to change that pmarie kondo says this one thing could be holding you back from falling in love pthis luxury credit card is only for truly big spenders pbanks have raised creditcard interest rates — but not savings account rates aheavy showers swamp new orleans street with rainwater loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  anth stock price  anthera pharmaceuticals inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers ctas  cof  etfc  syf  hp  isrg  hban  chk  latest newsall times eastern p updated ‘game of thrones’ the four biggest takeaways from stormborn’ p updated why you’re more likely to die in an accident during the summer months p updated these wealthy parents spend  for summer camps so their kids can be ‘normal’ p updated  totally avoidable reasons why millennials can’t have nice things or save any money p updated how elon musk and shorter commutes could transform people’s lives p updated john mccain is a war hero — but think twice before saying he’s ‘battling’ cancer p updated the dark side of cruises p updated at least  dead after overheated tractortrailer found outside texas walmart p ‘full transparency’ doesn’t mean what scaramucci apparently thinks it means p stocks brace for volatility in earnings deluge fed meeting looms to be replaced home investing quotes stocks united states anth overview compare quotes stock screener earnings calendar sectors nasdaq anth us nasdaq join td ameritrade find a broker anthera pharmaceuticals inc watchlist createanthalert closed last updated jul    pm edt delayed quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  k open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee na pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume k performance  day   month   month  ytd   year  recent news marketwatch other dow jones anthera pharmaceuticals downgraded at suntrust price target slashed to  from  dec   at  am et by ciara linnane anthera pharmaceuticals downgraded to hold vs buy at suntrust robinson humphrey dec   at  am et by ciara linnane anthera pharmaceuticals stock price target slashed to  vs  at suntrust robinson dec   at  am et by ciara linnane anthera pharma plunges  after missing target in study dec   at  pm et by jeremy c owens anthera pharma stock rises  on safety review boards goahead for latestage drug trial aug   at  am et by emma court dow industrials teeter on major technical support aug   at  pm et by michael ashbaugh alcoa shares rise slightly as revenue tops estimates jul   at  pm et by wallace witkowski  stocks to watch jun   at  pm et by harry boxer  cheapest stocks in the nasdaq’s hottest sector feb   at  am et by philip van doorn  stocks that are pushing the nasdaq to  feb   at  pm et by philip van doorn stock futures edge up after retail claims data dec   at  am et by victor reklaitis stocks to watch thursday libbey jm smucker jul   at  am et by marketwatch anthera cut to sell by citigroup jun   at  am et by greg morcroft thursday’s top gaining and declining stocks jun   at  pm et by marketwatch anthera plunges on drug study jun   at  am et by val brickates kennedy stocks to watch friday ups ak steel amerigas mar   at  am et by marketwatch monday’s biggest gaining and declining stocks mar   at  pm et by kate gibson anthera plunges  on failed study mar   at  am et by val brickates kennedy us stock futures fall before euroarea meeting mar   at  am et by barbara kollmeyer stocks to watch monday cocacola michael kors mar   at  am et by marketwatch clinical development news jan  jan   at  pm et on the wall street journal stocks to watch anthera pharma galena biopharma delta air dec   at  am et on the wall street journal the fundamental reason stocks could keep heading higher in  dec   at  am et on the wall street journal cfo moves anthem cornerstone ondemand may   at  pm et on the wall street journal stocks to watch oshkosh hasbro tempurpedic jan   at  am et on the wall street journal stocks to watch morgan stanley walgreen ebay jul   at  am et on the wall street journal tahoe resources anthera pharmaceuticals biggest price decliners taho anth jun   at  pm et on the wall street journal stocks to watch family dollar stores aol synergetics jun   at  am et on the wall street journal stocks to watch cogo perfect world anthera and more mar   at  am et on the wall street journal stocks to watch cogo perfect world anthera and more mar   at  am et on the wall street journal dow posts fourth straight gain mar   at  pm et on the wall street journal mcewen mining anthera pharmaceuticals biggest price decliners mux anth mar   at  pm et on the wall street journal verso paper anthera pharmaceuticals biggest price decliners vrs anth mar   at  pm et on the wall street journal stocks to watch zoll medical pacific capital youku mar   at  am et on the wall street journal china new borun anthera pharmaceuticals biggest price gainers born anth oct   at  pm et on the wall street journal companies turn to reverse stock splits ahead of ipos sep   at  pm et on the wall street journal bluelinx holdings anthera pharmaceuticals biggest price gainers bxc anth sep   at  pm et on the wall street journal steelcase anthera pharmaceuticals biggest price gainers scs anth sep   at  pm et on the wall street journal after a half century of work medicine for lupus may be near jun   at  pm et on the wall street journal first bancorp puerto rico anthera pharmaceuticals biggest price gainers fbp anth apr   at  pm et on the wall street journal recent news other news press releases anthera pharma to be opportunistic with capital raising anthera pharma to be opportunistic with capital raising jun   at  pm et on seeking alpha anthera continues down move shares off  anthera continues down move shares off  may   at  am et on seeking alpha axovant sciences axon shows strength stock jumps  apr   at  am et on zackscom anths anth blisibimod completes dosing in phase iii study apr   at  am et on zackscom should you get rid of aimmune therapeutics aimt now apr   at  am et on zackscom biotelemetry beat shows strength stock moves  higher apr   at  am et on zackscom cellect biotechnology apop jumps stock moves  higher apr   at  am et on zackscom bill ackman apologizes for valeant investment error mar   at  pm et on zackscom antheras sollpura on par with pancreaze in extension phase of latestage study in certain cf patients shares ahead  after hours mar   at  pm et on seeking alpha cara therapeutics cara shows strength stock up  mar   at  am et on zackscom will endos troubles continue to dent performance in  mar   at  pm et on zackscom astrazenecas lung cancer drug tagrisso approved in china mar   at  am et on zackscom merrimack mack starts enrollment in solid tumors study mar   at  pm et on zackscom shire shpg rare disease drug gets fast track designation mar   at  pm et on zackscom ovascience inc ovas looks good stock up  higher mar   at  am et on zackscom enzo biochem inc enz shows strength stock up  mar   at  am et on zackscom avexis inc avxs looks good stock moves  higher mar   at  am et on zackscom fortress biotech fbio catches eye stock moves up  mar   at  am et on zackscom valeant vrx shares up on valueacts  stake increase mar   at  pm et on zackscom implied volatility surging for anthera anth stock options mar   at  am et on zackscom anthera pharmaceuticals announces result phase  clinical study of sollpura will be included in the cystic fibrosis foundation therapeutics development network anthera pharmaceuticals announces result phase  clinical study of sollpura will be included in the cystic fibrosis foundation therapeutics development network jul   at  am et on globenewswire research reports coverage on biotech stocks  anthera pharma cara therapeutics cerus and concert pharma research reports coverage on biotech stocks  anthera pharma cara therapeutics cerus and concert pharma jun   at  am et on pr newswire  prf anthera pharmaceuticals provides business update and reports  first quarter financial results anthera pharmaceuticals provides business update and reports  first quarter financial results may   at  pm et on globenewswire anthera pharmaceuticals announces for reverse split of stock anthera pharmaceuticals announces for reverse split of stock apr   at  pm et on globenewswire anth shareholder alert the law offices of vincent wong reminds investors of commencement of a class action involving anthera pharmaceuticals inc and a lead plaintiff deadline of april   apr   at  am et on accesswire anthera announces completion of dosing in the phase  brightsc study of blisibimod in patients with iga nephropathy apr   at  am et on globenewswire deadline alert brower piven reminds investors of the upcoming deadline in class action lawsuit and encourages investors with losses in excess of  from investment in anthera pharmaceuticals inc to contact the firm apr   at  pm et on businesswire  bzx research reports initiation on biotech stocks  sarepta therapeutics galena biopharma anthera pharma and clovis oncology apr   at  am et on pr newswire  prf anthera announces positive results from the extension period of the solution study of sollpura mar   at  pm et on globenewswire shareholder alert brower piven encourages investors who have losses in excess of  from investment in anthera pharmaceuticals inc anth to contact brower piven before the lead plaintiff deadline in class action lawsuit mar   at  pm et on globenewswire anth shareholder alert the law offices of vincent wong reminds investors of a class action involving anthera pharmaceuticals inc and a lead plaintiff deadline of april   mar   at  am et on globenewswire anthera pharmaceuticals announces pricing of  million public offering of common stock and warrants mar   at  am et on globenewswire anthera pharmaceuticals announces proposed public offering of common stock and warrants mar   at  pm et on globenewswire shareholder alert levi  korsinsky llp reminds investors it has filed a complaint to recover losses suffered by investors in anthera pharmaceuticals inc mar   at  am et on globenewswire anthera pharmaceuticals provides business update and reports  fourth quarter and fiscal year financial results feb   at  pm et on globenewswire research reports coverage on biotech stocks  anthera pharma arrowhead pharma pacific biosciences of california and conatus pharma feb   at  am et on pr newswire  prf shareholder alert brower piven notifies investors of class action lawsuit and encourages those who have losses in excess of  from investment in anthera pharmaceuticals inc anth to contact brower piven before the lead plaintiff deadline feb   at  pm et on globenewswire johnson  weaver llp announces investigations of clovis oncology inc usana health sciences inc anthera pharmaceuticals inc and pixarbio corporation feb   at  pm et on pr newswire  prf robbins arroyo llp anthera pharmaceuticals inc anth misled shareholders according to a recently filed class action feb   at  pm et on businesswire  bzx shareholder alert levi  korsinsky llp has filed a complaint to recover losses suffered by investors in anthera pharmaceuticals inc feb   at  am et on globenewswire anthera pharmaceuticals inc anthera pharmaceuticals inc is a biopharmaceutical company which focuses on developing and commercializing products to treat serious and lifethreatening diseases including lupus lupus with glomerulonephritis iga nephropathy and exocrine pancreatic insufficiency due to cystic fibrosis it develops phase  product candidates which includes blisibimod and liprotamase anthera pharmaceuticals was founded by paul f truex on september   and is headquartered in hayward ca see full profile analyst ratings sell under hold over buy number of ratings  full ratings benzingas top initiations jul   at  am et on benzingacom the top  wall street analysts of  dec   at  am et on benzingacom in the sea of biotechs antheras multidrug pipeline makes it attractive sep   at  am et on benzingacom partner content trending tickers powered by bzun  gbtc  googl  mrk  nyt  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience press releases  anthera phone infoantheracom about us about us management board of directors scientific advisory board pipeline pipeline sollpura blisibimod publications clinical studies clinical studies solution simplicity bright · sc for investors corporate profile events  presentations press releases analyst coverage stock information corporate governance financials  filings investor contact contact us about us about us management board of directors scientific advisory board pipeline pipeline sollpura blisibimod publications clinical studies clinical studies solution simplicity chablissc for investors corporate profile events  presentations press releases analyst coverage stock information corporate governance financials  filings investor contact contact us go to about us about us management board of directors scientific advisory board pipeline pipeline sollpura blisibimod publications clinical studies clinical studies solution simplicity chablissc for investors corporate profile events  presentations press releases analyst coverage stock information corporate governance financials  filings investor contact contact us go to about us about us management board of directors scientific advisory board pipeline pipeline sollpura blisibimod publications clinical studies clinical studies solution simplicity chablissc for investors corporate profile events  presentations press releases analyst coverage stock information corporate governance financials  filings investor contact contact us press releases year all years              sort by date descending date ascending update   press releases   date title and summary view jul   anthera pharmaceuticals announces result phase  clinical study of sollpura will be included in the cystic fibrosis foundation therapeutics development network hayward calif july   globe newswire  anthera pharmaceuticals nasdaqanth today announced that the result phase  clinical study of sollpura for exocrine pancreatic insufficiency due to cystic fibrosis has been approved by the cystic fibrosis foundation therapeutics development network cff tdn protocol review committee the cff t pdf add to briefcase file is in briefcase jul   anthera announces expansion of screening in european sites in phase  result clinical study of sollpura study is being conducted in the us europe and israeltop line data expected end of  or early  hayward calif july   globe newswire  anthera nasdaqanth today announced that it has commenced screening in europe in the result phase  clinical study of sollpura for exocrine pancreatic insufficiency epi due to cystic fibros pdf add to briefcase file is in briefcase may   anthera announces first patient screened in result pivotal phase  clinical study of sollpura fourweek noninferiority coefficient of fat absorption cfa primary endpoint comparing sollpura to pancreaze in patients with exocrine pancreatic insufficiency due to cystic fibrosisstudy design leverages input from the us fda and cf communitytarget enrollment of  patients  years of age and oldertop line data expected end of  or early  pdf add to briefcase file is in briefcase may   anthera pharmaceuticals provides business update and reports  first quarter financial results result pivotal phase  study of sollpura is expected to screen the first patient in mayfavorable trends on weight height and body mass index bmi from the extension period of the solution study of sollpuracompletion of dosing in the phase  brightsc study of blisbimod in patients with iga nephropathyclosing of initial  million public off pdf add to briefcase file is in briefcase apr   anthera pharmaceuticals announces for reverse split of stock hayward calif april   globe newswire  anthera pharmaceuticals inc nasdaqanth announced today that it has filed a certificate of amendment to its amended and restated certificate of incorporation to effect a for reverse stock split of its common stock effective as of april   at  pm eastern time  a certificate  pdf add to briefcase file is in briefcase apr   anthera announces completion of dosing in the phase  brightsc study of blisibimod in patients with iga nephropathy hayward calif april   globe newswire  anthera pharmaceuticals nasdaqanth today announced the completion of dosing in the randomized doubleblind placebo controlled phase  brightsc study of blisibimod in patients with iga nephropathy igan  after week  patients were given the opportunity to continue blinded treatment fo pdf add to briefcase file is in briefcase mar   anthera announces positive results from the extension period of the solution study of sollpura sollpura demonstrated comparable maintenance in key measurements of height weight and bmisollpura was well tolerated throughout the week extension period hayward calif march   globe newswire  anthera pharmaceuticals inc nasdaqanth today announced the findings from the extension period of the phase  solution noninferior pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals announces pricing of  million public offering of common stock and warrants hayward calif march   globe newswire  anthera pharmaceuticals inc nasdaqanth the company today announced the pricing of an underwritten public offering of  shares of its common stock at a price of  per share and two tranches of warrants to purchase an aggregate of  shares of its common stock the gr pdf add to briefcase file is in briefcase mar   anthera pharmaceuticals announces proposed public offering of common stock and warrants hayward calif march   globe newswire  anthera pharmaceuticals inc nasdaqanth the company today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering  in addition the company intends to grant the underwriters a day op pdf add to briefcase file is in briefcase feb   anthera pharmaceuticals provides business update and reports  fourth quarter and fiscal year financial results solution study with sollpura™ missed noninferiority endpoint by  prompting new phase  studydata monitoring committee issued recommendation to continue simplicity study with sollpura™blisibimod for the treatment of iga nephropathy demonstrated positive trends at week blisibimod for the treatment of systemic lupus terminatedcraig t pdf add to briefcase file is in briefcase page      nextlast view  results per page  results per page  results per page update view  add release to briefcase corporate profile events  presentations press releases analyst coverage stock information corporate governance financials  filings investor contact facebook google linkedin twitter email rss anth key statistics  anthera pharmaceuticals inc financial ratios  marketwatch bulletin investor alert tokyo markets close in currencies europe markets london markets expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close anthera pharmaceuticals inc nasdaq anth go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus anthera pharmaceuticals inc market closed  quotes are delayed by  min jul    pm anth quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   company description anthera pharmaceuticals inc is a biopharmaceutical company which focuses on developing and commercializing products to treat serious and lifethreatening diseases including lupus lupus with glomerulonephritis iga nephropathy and exocrine pancreatic insufficiency due to cystic fibrosis it dev anthera pharmaceuticals inc is a biopharmaceutical company which focuses on developing and commercializing products to treat serious and lifethreatening diseases including lupus lupus with glomerulonephritis iga nephropathy and exocrine pancreatic insufficiency due to cystic fibrosis it develops phase  product candidates which includes blisibimod and liprotamase anthera pharmaceuticals was founded by paul f truex on september   and is headquartered in hayward ca valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  enterprise value to ebitda  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure officers and executives name age officer since title mr paul f truex   executive chairman mr john craig thompson   president chief executive officer  director ms may liu   cao senior vpfinance  administration dr william r shanahan   chief medical officer dr renee martin   senior vice presidentmedical science insider actions – purchase – sale  – number of transactions  date name shares transaction value  charles v olson chief technology officer    award at  per share   paul f truex chief executive officer    gift at  per share   paul f truex chief executive officer    derivativenonderivative trans at  per share   paul f truex chief executive officer    gift at  per share   charles v olson chief technology officer    award at  per share   brian r mueller director    derivativenonderivative trans at  per share   colin hislop chief medical officer    disposition at  per share   colin hislop chief medical officer    derivativenonderivative trans at  per share   colin hislop chief medical officer    disposition at  per share   debra a odink chief technology officer    disposition at  per share   paul f truex chief executive officer    gift at  per share   paul f truex chief executive officer      paul f truex chief executive officer      paul f truex chief executive officer    award at  per share   may liu svp finance  administration    award at  per share   klara a dickinsoneason svp  chief regulatory office    award at  per share   paul f truex chief executive officer    gift at  per share   paul f truex chief executive officer    gift at  per share   debra a odink chief technology officer    gift at  per share   debra a odink chief technology officer    gift at  per share  newslatestcompanyusanth marketwatch news on anth anthera pharmaceuticals downgraded at suntrust price target slashed to  from   am dec    ciara linnane anthera pharmaceuticals downgraded to hold vs buy at suntrust robinson humphrey  am dec    ciara linnane anthera pharmaceuticals stock price target slashed to  vs  at suntrust robinson  am dec    ciara linnane anthera pharma plunges  after missing target in study  pm dec    jeremy c owens anthera pharma stock rises  on safety review boards goahead for latestage drug trial  am aug    emma court dow industrials teeter on major technical support  pm aug    michael ashbaugh alcoa shares rise slightly as revenue tops estimates  pm july    wallace witkowski  stocks to watch  pm june    the trading deck  cheapest stocks in the nasdaq’s hottest sector  pm feb    philip van doorn  stocks that are pushing the nasdaq to   pm feb    philip van doorn stock futures edge up after retail claims data  am dec    victor reklaitis stocks to watch thursday libbey jm smucker  am july    marketwatch anthera cut to sell by citigroup  am june    greg morcroft thursday’s top gaining and declining stocks  pm june    marketwatch anthera plunges on drug study  am june    val brickates kennedy stocks to watch friday ups ak steel amerigas  am march    marketwatch monday’s biggest gaining and declining stocks  pm march    kate gibson anthera plunges  on failed study  am march    val brickates kennedy us stock futures fall before euroarea meeting  am march    barbara kollmeyer stocks to watch monday cocacola michael kors  am march    marketwatch loading more headlines newsnonmarketwatchcompanyusanth other news on anth anthera pharma to be opportunistic with capital raising  pm june    seeking alpha anthera continues down move shares off   am may    seeking alpha axovant sciences axon shows strength stock jumps   am april    zackscom anths anth blisibimod completes dosing in phase iii study  am april    zackscom should you get rid of aimmune therapeutics aimt now  am april    zackscom biotelemetry beat shows strength stock moves  higher  am april    zackscom cellect biotechnology apop jumps stock moves  higher  am april    zackscom bill ackman apologizes for valeant investment error  pm march    zackscom antheras sollpura on par with pancreaze in extension phase of latestage study in certain cf patients shares ahead  after hours  pm march    seeking alpha cara therapeutics cara shows strength stock up   am march    zackscom will endos troubles continue to dent performance in   pm march    zackscom astrazenecas lung cancer drug tagrisso approved in china  am march    zackscom merrimack mack starts enrollment in solid tumors study  pm march    zackscom shire shpg rare disease drug gets fast track designation  pm march    zackscom ovascience inc ovas looks good stock up  higher  am march    zackscom enzo biochem inc enz shows strength stock up   am march    zackscom avexis inc avxs looks good stock moves  higher  am march    zackscom fortress biotech fbio catches eye stock moves up   am march    zackscom valeant vrx shares up on valueacts  stake increase  pm march    zackscom implied volatility surging for anthera anth stock options  am march    zackscom loading more headlines at a glance anthera pharmaceuticals inc  industrial boulevard suite b hayward california  phone   industry biotechnology sector health carelife sciences fiscal yearend  view sec filings revenue  net income m employees  annual report for anth newspressreleasecompanyusanth press releases on anth anthera pharmaceuticals announces result phase  clinical study of sollpura will be included in the cystic fibrosis foundation therapeutics development network  am july    globenewswire anthera announces expansion of screening in european sites in phase  result clinical study of sollpura  am july    globenewswire research reports coverage on biotech stocks  anthera pharma cara therapeutics cerus and concert pharma  am june    pr newswire  prf anthera announces first patient screened in result pivotal phase  clinical study of sollpura  pm may    globenewswire anthera pharmaceuticals provides business update and reports  first quarter financial results  pm may    globenewswire anthera pharmaceuticals announces for reverse split of stock  pm april    globenewswire anth shareholder alert the law offices of vincent wong reminds investors of commencement of a class action involving anthera pharmaceuticals inc and a lead plaintiff deadline of april    am april    accesswire anthera announces completion of dosing in the phase  brightsc study of blisibimod in patients with iga nephropathy  am april    globenewswire deadline alert brower piven reminds investors of the upcoming deadline in class action lawsuit and encourages investors with losses in excess of  from investment in anthera pharmaceuticals inc to contact the firm  pm april    businesswire  bzx research reports initiation on biotech stocks  sarepta therapeutics galena biopharma anthera pharma and clovis oncology  am april    pr newswire  prf anthera announces positive results from the extension period of the solution study of sollpura  pm march    globenewswire shareholder alert brower piven encourages investors who have losses in excess of  from investment in anthera pharmaceuticals inc anth to contact brower piven before the lead plaintiff deadline in class action lawsuit  pm march    globenewswire anth shareholder alert the law offices of vincent wong reminds investors of a class action involving anthera pharmaceuticals inc and a lead plaintiff deadline of april    am march    globenewswire anthera pharmaceuticals announces pricing of  million public offering of common stock and warrants  am march    globenewswire anthera pharmaceuticals announces proposed public offering of common stock and warrants  pm march    globenewswire shareholder alert levi  korsinsky llp reminds investors it has filed a complaint to recover losses suffered by investors in anthera pharmaceuticals inc  pm march    globenewswire anthera pharmaceuticals provides business update and reports  fourth quarter and fiscal year financial results  pm feb    globenewswire research reports coverage on biotech stocks  anthera pharma arrowhead pharma pacific biosciences of california and conatus pharma  am feb    pr newswire  prf shareholder alert brower piven notifies investors of class action lawsuit and encourages those who have losses in excess of  from investment in anthera pharmaceuticals inc anth to contact brower piven before the lead plaintiff deadline  pm feb    globenewswire johnson  weaver llp announces investigations of clovis oncology inc usana health sciences inc anthera pharmaceuticals inc and pixarbio corporation  pm feb    pr newswire  prf loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo open marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest p‘game of thrones’ the four biggest takeaways from stormborn’ pwhy you’re more likely to die in an accident during the summer months pthese wealthy parents spend  for summer camps so their kids can be ‘normal’ p totally avoidable reasons why millennials can’t have nice things or save any money phow elon musk and shorter commutes could transform people’s lives pjohn mccain is a war hero — but think twice before saying he’s ‘battling’ cancer pthe dark side of cruises pat least  dead after overheated tractortrailer found outside texas walmart p‘full transparency’ doesn’t mean what scaramucci apparently thinks it means pstocks brace for volatility in earnings deluge fed meeting looms pif you suddenly quit your job like sean spicer here’s what you should do next pnever ever say these things to a coworker pmy uncle with dementia needs longterm care — should i refinance his house pthis is the deadliest time of your life to put on weight pwhy house prices in gay neighborhoods are soaring pnearly  of adults don’t have life insurance — these startups are trying to change that pmarie kondo says this one thing could be holding you back from falling in love pthis luxury credit card is only for truly big spenders pbanks have raised creditcard interest rates — but not savings account rates aheavy showers swamp new orleans street with rainwater loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  anthnasdaq gm stock quote  anthera pharmaceuticals inc  bloomberg markets error could not add to watchlist x  watchlist anthera pharmaceuticals inc anthus nasdaq gm usd   as of  pm edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap m usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases  antheras sollpura on par with pancreaze study  investopedia there are currently no news stories for this ticker please check back later  anthera pharmaceuticals announces result phase  clinical study of sollpura will be included in the cystic fibrosis foundation  anthera announces expansion of screening in european sites in phase  result clinical study of sollpura  anthera announces first patient screened in result pivotal phase  clinical study of sollpura  anthera pharmaceuticals provides business update and reports  first quarter financial results  anthera pharmaceuticals announces for reverse split of stock  anthera announces completion of dosing in the phase  brightsc study of blisibimod in patients with iga nephropathy  deadline alert brower piven reminds investors of the upcoming deadline in class action lawsuit and encourages investors with  anthera announces positive results from the extension period of the solution study of sollpura  anth investor alert the law offices of vincent wong reminds investors of a class action involving anthera pharmaceuticals inc  shareholder alert brower piven encourages investors who have losses in excess of  from investment in anthera pharmaceu there are currently no press releases for this ticker please check back later profile anthera pharmaceuticals inc is a biopharmaceutical company focused on developing and commercializing products to treat serious and lifethreatening diseases including lupus lupus with glomerulonephritis iga nephropathy and exocrine pancreatic insufficiency due to cystic fibrosis address  industrial blvdsuite bhayward ca united states phone  website wwwantheracom executives board members paul f truex chairmanfounder j craig thompson presidentceo charles v olson chuck senior vpcto william r shanahan senior vpchief med ofc may liu senior vpfinance  administration show more anthera pharmaceuticals – pharmaceuticals to benefit patients with unmet medical needs phone infoantheracom working for the end ofburdensomeepi treatmentslearn about antheras developmental nextgeneration pancreatic enzyme replacement therapylearn morea new path foriga nephropathypatientslearn how anthera pharmaceuticals is developing the worlds first therapy to address the root cause of iganlearn more anthera homepage siteadministrator t anthera pharmaceuticals  we are focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs find out more about what we are doing for patients with cystic fibrosis and iga nephropathy cystic fibrosisiga nephropathy latest newsanthera pharmaceuticals announces result phase  clinical study of sollpura will be included in the cystic fibrosis foundation therapeutics development network read more anthera pharmaceuticals announces expansion of screening in european sites in phase  result clinical study of sollpura read more bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one